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9ABSTRACT
An active intraocular renin-angiotensin system (RAS) has recently been shown to
exist in the human eye and evidence is now accumulating that antihypertensive
drugs acting on RAS can also lower intraocular pressure (IOP), though no agents are
as yet in ophthalmological use. The aim of this experimental study was to elucidate
the expression and function of RAS in the eye tissues and in the regulation of IOP.
The expression of ocular RAS was evaluated by RT-PCR, in vitro autoradiography
and fluorometric assay. The functional RAS was investigated after administration of
different RAS compounds by the two-level constant pressure method of Bárány and
by IOP measurement using pneumatonometer or rebound tonometer. Experimental
animals were ocular normotensive rabbits and rats. Enucleated fresh porcine eyes
were used in enzyme activity determinations.The potential relationship between
developing blood pressure and intraocular pressure as well as the effect of general
anesthesia on IOP was evaluated using arterial hypertensive rat strains and their
normotensive controls.
The main finding in this study was a heptapeptide angiotensin (1-7) (Ang (1-7)),
which when administered intravitreally significantly reduced IOP in the normotensive
rabbit eye. Its specific receptor, the Mas receptor, was for the first time found in the
eye structures. A third finding in respect of intraocular RAS was the existence of
ACE2 in vitreous and ciliary bodies in addition to the earlier demonstration of its
retinal activity.
The present findings suggest the potential as future antiglaucomatous agents of
components which increase intraocular ACE2 activity and the formation of Ang (1-7),
or activate Mas receptors.
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1 INTRODUCTION
The Finnish physiologist Tigerstedt and his coworker Bergman described for
first time a pressor substance which they found in the rabbit kidney and named
renin (Tigerstedt and Bergman 1898). In 1940 groups under Braun-Menéndez
and Page reported that renin was the enzyme acting on a plasma protein
substrate to catalyze the formation of the actual pressor peptide, first named
hypertensin or angiotonin (Braun-Mendez et al. 1939; Page and Helmer 1940).
Later the pressor substance was renamed angiotensin and the plasma
substrate angiotensinogen (Jackson 2006).
Once angiotensin II (Ang II) was found, its important role in the regulation of
blood pressure was soon recognized. In 1958 the German investigator Gross
perceived a larger system when aldosterone synthesis and secretion were
shown to be involved in the renin-angiotensin system (RAS) (Gross and Lichtlen
1958a,b; Gross and Schmidt 1958). In the 1970s the development of
antihypertensive drugs commenced. First to be evolved were angiotensin-
converting enzyme (ACE) inhibitors, which prevent the formation of Ang II
(Ondetti et al. 1977), and in 1988 in the laboratory of DuPont Merck Ang II
receptor type 1 blockers, which prevent the direct effects of Ang II. Both drugs
acting on RAS are today the most widely used drugs in the treatment of
hypertension (Hall 2003). In the future, renin blockers, agents inhibiting the
whole renin-angiotensin system, may gain ground in the field of
antihypertensive treatment (Triller et al. 2008).
Ang II is a potent vasoconstrictor and is traditionally regarded as the main
effector peptide in the RAS. According to recent studies, however, the final
effect of RAS activation is more complex, being based on the biological activity
of Ang II and the activities of the other products of angiotensinogen metabolism,
often exerting opposite effects on Ang II action (Kramkowski et al. 2006; Paul et
al. 2006). Evidence is accummulating indicating the existence of local RAS
systems which regulate long-term changes in a number of organs, e.g. the
vasculature, adrenal gland, kidney, brain, testis and ovary via the activity of
other angiotensins and their receptors (Deschepper et al. 1986; Derkx et al.
1987). An active intraocular RAS has also been described in the human eye
(Sramek et al. 1992; Danser et al. 1994). Drugs acting on the RAS have been
reported to be able to lower IOP (Costagliola et al. 1995; Costagliola et al. 2000;
Shah et al. 2000; Inoue et al. 2001a; Wang et al. 2005a), but no RAS agents
are as yet in ophthalmological use. These preliminary findings would suggest
that the RAS not only regulates blood pressure but is also involved in the
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regulation of IOP. However, the exact mechanism of this action is as yet not
known.
The present study was sought to clarify in greater detail the expression and
function of RAS in the eye tissues and in the regulation of IOP.
REVIEW OF THE LITERATURE
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2 REVIEW OF THE LITERATURE
2.1 CIRCULATING RENIN-ANGIOTENSIN SYSTEM
The complexity of the present knowledge of RAS is depicted in Figure 1.
2.1.1 Angiotensins
1          2       3      4      5       6       7         8        9      10       11    12     13    14
Angiotensinogen (NH2-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Ser-
R)
The obligatory substrate for the whole RAS is angiotensinogen, an ?-
glycoprotein consisting of 255 amino acids, synthesized in and released from
the liver and cleaved in the circulation by an enzyme called renin (Nasjletti and
Masson 1971; Tewksbury et al. 1978). In addition to the main synthesis in the
liver, angiotensinogen can also be synthesized at tissue level (Paul et al. 2006;
Iusuf et al. 2008). Synthesis of angiotensinogen is stimulated, in addition to
angiotensin II (Ang II), by for example inflammation, insulin, estrogens,
glucocorticoids and thyroid hormone (Jackson 2006).
Renin
Renin is an aspartyl protease whose principal natural substrate is the circulating
?-glycoprotein angiotensinogen. Renin is synthesized in the juxtaglomerular
apparatus of the kidney as a preproenzyme of 406 amino acid residues that is
attributed to prorenin, a mature but inactive form of the protein. The active form
of renin consists of 340 amino acids, and is capable of cleaving the bond
between residues 10 (=Leu) and 11 (=Val) at the amino terminus of
angiotensinogen to generate the decapeptide angiotensin I (Ang I) (Morris
1986; Jackson 2006). Renin secretion is influenced by the pressure in the renal
artery, by the activity of the sympathetic nervous system, and by the still
hypothetical macula densa signal as well as by humoral factors. Renin-
synthesizing cells are present not only in the kidney but also in a number of
other organs, e.g. brain, pituitary and adrenal glands, heart, arterial smooth
muscle, testis (Ganten et al. 1976; Hackenthal et al. 1990) and eye (Danser et
al. 1989; Wagner et al. 1996). Renin is an important enzyme in the RAS for the
cleavage of angiotensinogen to Ang  I and further to more bioactive forms of
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RAS (Satofuka et al. 2006; Iusuf et al. 2008).  The inactive precursor of renin,
prorenin, is released constitutively from the kidney. Its plasma levels are
approximately 10-100-fold greater than those of renin and its action on RAS is
probably marked not only via renin but also via renin receptors (Batenburg et al.
2007; Nguyen and Danser 2008). Prorenin can be activated in two ways:
proteolytic or non-proteolytic, the first being irreversible and the latter reversible
depending e.g. on temperature and pH (Nguyen and Danser 2008).
 1        2       3        4      5       6        7         8       9      10
Angiotensin I (Ang I, Ang 1-10) (NH2-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-
COOH)
Ang I is a decapeptide formed from angiotensinogen by activation of renin. Ang
I is a precursor for Ang II and a weak vasoconstrictor. It is further cleaved to the
more potent octapeptide Ang II mainly by angiotensin-converting enzyme
(ACE), which removes the carboxyterminal dipeptide His-Leu of Ang I (Skeggs
et al. 1956; Vickers et al. 2002). This cleavage can also be brought about by
other enzymes such as CAGE, chymase and cathepsin G (Figure 1). These
alternative routes via other enzymes are called renin-independent or ACE-
independent pathways for Ang II production (Kramkowski et al. 2006).
Angiotensin-converting enzyme (ACE, ACE1, kininase II, dipeptidyl
carboxy-peptidase)
ACE, a membrane-bound proteinase containing 1277 amino acid residues, is
predominantly expressed in high concentrations on the surface of endothelial
cells in the pulmonary circulation and has a significant role in circulating RAS,
forming Ang II from Ang I, and in degrading other angiotensins to inactive forms.
Its important role is to catalyze the cleavage of the dipeptide His-Leu from the
carboxyl terminus of Ang I  (Skeggs et al. 1956; Ng and Vane 1967). Its main
effect is strongly vasopressive (Sealey and Laragh 1990). ACE is also known as
kininase II, as it also catalyzes the bradykinin cascade (Su 2006), having a
degrading effect on the vasodilatory bradykinin (Jackson 2006; Kramkowski et
al. 2006). Bradykinin is a nonapeptide formed from kininogens mainly produced
by hepatocytes. It dilates blood vessels by stimulating the production e.g. of
nitric oxide and prostacyclin in the vascular endothelium (Su 2006), or via direct
effects through B2 receptors (Berguer et al. 1993).
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1         2         3       4       5       6          7         8
Angiotensin II (Ang II, Ang 1-8) (NH2-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-
COOH)
Ang II (Braun-Mendez et al. 1939; Page and Helmer 1940) is a potent
vasoconstrictor and is traditionally considered to be the main effector peptide in
the circulating RAS. It is an octapeptide formed from Ang I mainly by ACE  or
other enzymes such as CAGE (chymostatin-sensitive Ang II-generating
enzyme), chymase, cathepsin G or directly from the long polypeptide chain,
angiotensinogen, by alternative pathways catalyzed by catepsin G, tonin,
trypsin or chymotrypsin (Kramkowski et al. 2006; Paul et al. 2006). Ang II has
three major physiological effects which are linked to blood pressure and
electrolyte homeostasis: vasoconstriction, renal tubular sodium reabsorption
and aldosterone biosynthesis.
Importantly Ang II has proinflammatory characteristics (Mervaala et al. 2000;
Ruiz-Ortega et al. 2001). It stimulates free radical production, plasminogen
activator inhibitor-1 release and tissue factor and adhesion molecule
expression. It is considered to diminish the beneficial effects of nitric oxide by
inhibiting nitric oxide synthase (eNOS). In blood vessels, it stimulates smooth
muscle cell proliferation and leukocyte activation (Buczko 1999; Jackson 2006).
These are essential factors in the pathogenesis of hypertension though the
mechanism of RAS-induced hypertension has also been attributed to the direct
effects of Ang II on angiotensin II type 1 (AT1) receptors in vascular smooth
muscle (Sealey and Laragh 1990; Paul et al. 2006) and stimulation of the
release of aldosterone, a mineralocorticoid emanating from the adrenal cortex
(Laragh et al. 1960; Sealey et al. 1978).  Thus Ang II elevates blood pressure
by releasing noradrenaline from adrenergic nerve endings, endothelin 1, a
potent vasoconstrictor, from the endothelium (Sung et al. 1994) and
vasopressin, a vasoconstricting pituitary hormone, as well as by reducing
baroreceptor activity (Sealey and Laragh 1990; Ardaillou 1997). The half-life of
Ang II is short, only a couple of seconds (Al-Merani 1978). Its vasopressive
effects appear rapidly and are more long-lasting.
      2       3       4       5       6         7        8
Angiotensin III (Ang 2-8, Ang III) (NH2-Arg-Val-Tyr-Ile-His-Pro-Phe-COOH)
Ang III is formed from Ang II or angiotensin (2-10) by aminopeptidase A and
ACE. Similarly to Ang II, Ang III is also a vasoconstrictor, albeit less potent. Ang
III is only 25 % as potent as Ang II in elevating blood pressure and 10 % in
stimulating the adrenal medulla (Jackson 2006).
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              3        4      5      6         7         8
Angiotensin IV (Ang IV, Ang 3-8) (NH2-Val-Tyr-Ile-His-Pro-Phe-COOH)
Ang IV is formed from Ang III or directly from Ang II by aminopeptidase
activities. In contrast to Ang II, Ang IV is held to be a vasorelaxing agent. It also
has cell-proliferative properties and may be involved in vascular inflammatory
responses (Ruiz-Ortega et al. 2007). Its activation may also be involved in
memory and neuronal development (Mustafa et al. 2001).  The precise
mechanism and function of Ang IV is not clear, but its vasodilatatory effect is
explained by activation of endothelial nitric oxide synthase (Kramkowski et al.
2006).
Angiotensin-converting enzyme 2 (ACE2)
ACE2 is an important counter-regulatory factor in RAS especially at tissue level
(Donoghue et al. 2000; Yagil and Yagil 2003). This is discussed in grater detail
in section 2.2.2.
               1          2       3        4       5       6        7         8         9
Angiotensin (1-9) (Ang (1-9)) (NH2-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-
COOH)
Ang (1-9) is formed from Ang I by activation of ACE2, which cleaves one amino
acid  (Leu) from the carboxyl terminus of Ang  I. Ang (1-9) has recently been
found and its function is not yet clear, but it is a strong inhibitor of ACE and
serves as a substrate fot the formation of angiotensin (1-7) (Ang (1-7)) (Mustafa
et al. 2001; Iusuf et al. 2008). It activates bradykinin, increases nitric oxide
formation and release of the eicosanoid precursor arachidonic acid, and is
possibly involved in the inhibition of platelet function (Donoghue et al. 2000).
1         2        3        4      5        6        7
Angiotensin (1-7) (Ang (1-7)) (NH2-Asp-Arg-Val-Tyr-Ile-His-Pro-COOH)
Ang (1-7), formed from Ang II by ACE-independent enzymes (Welches et al.
1993; Santos et al. 2000), was first discovered more than 30 years ago (Semple
et al. 1976a; Semple et al. 1976b; Ferrario et al. 1988) and is one of the
products of RAS most extensively investigated in recent years (Ferrario and
Chappell 2004). It can also be synthesized directly from Ang  I or Ang (1-9),
bypassing the synthesis of Ang II (Kucharewicz et al. 2002), or from a
prohormone angiotensin (1-12) (Ang (1-12)), which is proposed to serve as a
precursor for Ang (1-7) (Nagata at al. 2006). The enzymes catalyzing the
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degradation of Ang I and II to form Ang (1-7) are ACE2 and endopeptidases
such as neprilysin and prolylcarboxy-peptidase. These enzymes cleave Phe-
His-Leu from Ang I and Phe from Ang II. Ang (1-7) is further metabolized to
smaller peptides; to angiotensin (1-5) or to angiotensin (3-7) by ACE (Roks et
al. 1999). Ang (1-7) is a biologically active heptapeptide with high selectivity.  In
most situations, Ang (1-7) and Ang II exert opposing actions, suggesting a
primary role for Ang (1-7) as a counter-regulatory component for the vascular
and proliferative actions of Ang II (Iwata et al. 2005; Kostenis et al. 2005). Ang
(1-7) promotes release of prostanoids from endothelial and smooth muscle cells
(Muthalif et al. 1998), release of nitric oxide (Seyedi et al. 1995), vasorelaxation
and inhibition of vascular cell growth (Jaiswal et al.1992). Ang (1-7) also
exhibits an important stimulatory interaction with the kallikrein-kinin system, and
has thus a vasodilatory effect (Brosnihan et al. 1996). This mechanism is
complex, involving bradykinin receptor activation and inhibition of ACE, and the
release of nitric oxide and/or prostanoids. On the other hand, Ang (1-7) may be
a component in the endogenous regulation of tissue growth (Santos et al.
2000).
REVIEW OF THE LITERATURE
18
Figure 1.
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Figure 1. The renin-angiotensin system. ACE = angiotensin-converting enzyme,
ACE2 = angiotensin-converting enzyme-related carboxypeptidase, Ang I,II,III,IV=
angiotensin I,II,III,IV, Ang (1-10) = angiotensin (1-10), Ang (1-8) = angiotensin (1-
8), Ang (2-8) = angiotensin (2-8), Ang (3-8) = angiotensin (3-8), Ang (1-9) =
angiotensin (1-9), Ang (1-7) = angiotensin (1-7), Ang (1-5) = angiotensin (1-5), Ang
(3-7) = angiotensin (3-7), AT1 = angiotensin II type 1 receptor, AT2 = angiotensin
II type 2 receptor, AT4 = angiotensin II type 4 receptor, AP =aminopeptidase (-A,-
N,-M,-B), B1/B2 = bradykinin receptors, CAGE = chymostatin-sensitive Ang-II
generating enzyme, Mas-receptor = Ang (1-7) receptor type,  Nep = neprilysin,
PEP = prolyl endopeptidase, PCP = prolylcarboxy-peptidase, tPA = tissue-type
plasminogen activator (Vaajanen et al. 2008, modified version).
2.1.2 Angiotensin receptors
The effects of angiotensins are exerted through specific heptahelical G-protein-
coupled receptors which contain seven transmembrane regions (de Gasparo et
al. 2000; Burnier 2001). Ang II receptors in the cardiovascular system are
classically divided into two main subtypes: Ang II type  1  (AT1)  and  2  (AT2)
receptors, but evidence is accumulating to indicate the importance of other
receptor types such as Mas- and AT4 receptors (Santos et al. 2003, Ruiz-
Ortega et al. 2007). Generally adult tissues contain primarily AT1 receptors, AT2
receptors being represented especially in developing fetal tissues, and their
number decreases rapidly in the postnatal period (Timmermans et al. 1993a).
The AT1 receptor is 359 amino acids long, and has only about 30 % sequence
homology to the AT2 receptor type (Burnier 2001; Jackson 2006).
Ang II receptor type 1 (AT1 receptor)
Most of the known biological effects of Ang II are mediated by the AT1 receptors
in cardiovascular, renal, neuronal, endocrine, hepatic and other target cells,
which are specifically blocked by AT1 receptor antagonists, widely used as
antihypertensive drugs, “sartans” (de Gasparo et al. 2000; Burnier 2001).  The
first angiotensin receptors were cloned in 1991 (Murphy et al. 1991). Ang II
binding to the AT1 receptor induces a conformational change in the receptor
molecule which promotes its interaction with the G-protein(s), which in turn
mediate signal transduction via several plasma membrane effector systems (de
Gasparo et al. 2000). In rodents, the AT1-receptors are further divided into AT1a
and AT1b receptors (Kakar et al. 1992), which are 95% identical in amino acid
sequence (de Gasparo et al. 2000). These two subtypes have been reported to
have similarities in their ligand binding and activation properties but to differ in
their tissue distribution. The AT1 receptor contains a polymorphism reportedly
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associated with hypertension (Timmermans et al.1993b; Kainulainen et al.
1999).
Ang II receptor type 2 (AT2 receptor)
AT2 receptors are less well characterized than AT1 receptors, but are considered
to be cardiovascular protective receptors which antagonize the effects of Ang II
mediated via AT1 receptors.  They were first found and cloned in the 1990s
(Kambayashi et al. 1993; Nakajima et al. 1993). The AT2 receptors are clearly
distinct from the AT1 receptors in tissue-specific expression and in signalling
mechanism, but like other angiotensin receptors they belong to the superfamily
of G-protein-coupled receptors (de Gasparo et al. 2000). AT2 receptors may
exert the antiproliferative, proapoptotic, vasodilatory and antihypertensive
effects of angiotensins, and they evidently have an important role in prenatal
development (de Gasparo 2000; Jackson 2006). These receptors seem to be
re-expressed and up-regulated in some pathological conditions in adults, for
example cardiac hypertrophy, myocardial infarction and wound healing (Mizoue
et al. 2006; Oishi et al. 2006). PD123,319 is a selective AT2 receptor antagonist
(Ford et al. 1996) and CGP 42112A is a selective agonist for this receptor type
(Ewert et al. 2003).
Ang II receptor type 3 (AT3 receptor)
The role and function of AT3 receptors is not known, but they are reported to be
present in neuroblastoma cells in amphibians (Burnier 2001).
Ang II receptor type 4 (AT4 receptor)
An AT4 receptor type is known to be involved in cardiovascular pathology. It is
considered to be a target receptor especially for Ang IV, which can be
generated by degradation of Ang II, by aminopeptidases or by other proteases,
which in turn could be activated during tissue damage, suggesting that elevated
Ang IV levels will be found in pathologic conditions. (Mustafa et al. 2001; Ruiz-
Ortega et al. 2007). On the other hand, AT4 is also a target receptor for Ang (3-
7), which is a break-down product of vasorelaxing Ang (1-7) (Handa 2000).
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Mas receptor
The Mas-receptor was first found in the mouse kidney and subsequently in
other organs, e.g. heart, brain and vasculature (Santos et al. 2003; Iwata et al.
2005). Ang (1-7) is held to be an endogenous ligand for this receptor type
(Santos et al. 2003), which is distinct from the AT1 and AT2 receptors. It is a G
protein-coupled receptor encoded by the Mas protooncogene.  It mediates a
number of the positive cardiovascular effects of Ang (1-7), namely
vasodilatation, antiproliferation and antifibrosis, and it has a role in fluid volume
homeostasis. In vivo the Mas receptor acts antagonistically to the AT1 receptor,
and in addition can hetero-oligomerize with the AT1 receptor and thereby inhibit
the actions of Ang II (Kostenis et al. 2005). AVE 0991 is another known agonist
for the Mas receptor and it can mimic some effects of Ang (1-7) (Pinheiro et al.
2004; Lemos et al. 2005). At least two known antagonists for the Mas receptor
have been identified as D-Ala7-angiotensin (1-7) (A779) and Pro7-angiotensin-
(1-7) (Silva et al. 2007).
2.1.3 Blood pressure
The circulating RAS has an essential role in the regulation of blood pressure
and body fluid balance. RAS acts as a feedback system, in which Ang II is
traditionally considered the main regulatory peptide and ACE the main
regulatory enzyme and AT1 the main regulatory receptor.  In respect of
regulation of blood pressure the most important actions of Ang II are
vasoconstriction, sympathetic nervous stimulation, increased aldosterone
biosynthesis and renal actions (Fyhrquist et al. 1995; Luft 2001). These Ang II
effects elicit tissue responses mainly via AT1 receptors (Hirsch et al. 1990;
Crowley et al. 2007). In fact, according to recent evidence the circulating RAS is
not held to be directly responsible for the rise in blood pressure especially in
essential hypertension in elderly people, there being more important non-
circulating “local” renin-angiotensin systems, which have important roles in
regulating blood pressure and regional blood flow (Beevers et al. 2001). Local
tissue RAS is discussed in section 2.2. In other words, there are angiotensins
and enzymes other than Ang II and ACE at tissue level which are  involved in
the regulation of blood pressure as counter-regulatory factors to Ang II, e.g.
ACE2 and Ang (1-7) (Grobe et al. 2007; Ferreira and Raizada 2008).
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Hypertension
Arterial hypertension is a major modifiable risk factor for cardiovascular,
cerebrovascular and renal disease and mortality. The worldwide prevalence of
hypertension in the adult population was about 26% in 2000, and is increasing
in economically developed countries concomitantly with increasing age, obesity
and less physical activity (Kearney et al. 2005). About 95 % of hypertensive
subjects suffer from an essential, idiopathic hypertension whose etiology
remains unknown. The remaining 5 % are secondary to a specific reason for
high pressure. The most important etiological factors are renal and renovascular
reasons. There is no specific level of blood pressure where end organ
complications set in, but a pressure level over 140/90 mmHg in repeated
measurements is regarded as a risk level for most individuals (Carretero and
Oparil 2000a; Hemmelgarn et al. 2006). On the other hand, genetic factors have
been estimated to account for about 30 % of variation in blood pressure
(Beevers et al. 2001). According to the World Health Organization and the
International Sociey of Hypertension (WHO-ISH 2003) the limits of normal
hypertension are more strict the upper limits being 130/85 mmHg (Whitworth
2003).
As the name of the RAS (renin-angiotensin system) would indicate, renin plays
an important role in the regulation of blood pressure via control of systemic Ang
II levels. Measured renin levels correlate with the circadian rhythm of normal
blood pressure, which is at a lower level during the night (Stern et al. 1986;
Hamada et al. 2008). Observations to the contrary have been reported:
especially in elderly hypertensive people RAS and renin activity seem to be at
lower levels (Beevers et al. 2001). Although the precise etiology of hypertension
is not known, drugs acting on RAS, e.g. ACE-inhibitors and AT1 receptor
blockers, are among the most potential, clinically used antihypertensive agents.
2.1.4 Angiotensin-converting enzyme (ACE)- inhibitors
The development of ACE inhibitors began over 40 years ago when teprotide
was first discovered in the poison of Bothrops jararaca snake in Brazil (Ferreira
1965). Teprotide was perceived to inhibit kininase II, but only when
administered intravenously. About ten years later the first oral ACE inhibitor,
captopril, was developed (Ondetti et al. 1977). Nowadays ACE inhibitors like
captopril are widely used in the treatment of hypertension as well as of heart
insufficiency. Their positive cardiovascular effects are especially advantageous
in hypertensive patients with diabetes mellitus type 2 and nephropathy, in that
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they reduce proteinuria and delay the development of renal diseases
(Schmieder et al. 2007). The mechanism of action of ACE inhibitors is targeted
to inhibit the function of angiotensin-converting enzyme, formation of Ang II
being inhibited (Ruskoaho 1984), this also, however, leading to increased
plasma bradykinin levels. ACE inhibitors do not inhibit the action of ACE2, and
thus the vasorelaxing effects of Ang (1-7) and bradykinin cascade remain intact
(Carretero and Oparil, 2000b; Burnier 2001). On the other hand, bradykinin can
be involved in adverse effects of ACE inhibitors, for example cough and
angioedema (Nussberger et al. 1998).
2.1.5 Ang II receptor type 1 blockers (ARB)
The  very  first  AT1 receptor blocker was saralasin, a non-selective peptidic
antagonist of Ang II which when administered intravenously made it possible to
investigate angiotensin receptors even at the beginning of the 1970s. The first
oral AT1 receptor antagonist, losartan, was developed by DuPont Merck
Laboratories in 1988 after the finding of ACE inhibitors. In recent years,
numerous orally active AT1 receptor antagonists have been synthesized. These
antagonists, also called Ang II receptor  type  1  blockers  (ARB),  are  used
especially in the treatment of hypertension, heart failure and renal disease, and
they have overall a high affinity to the AT1 receptors when the function of these
receptors is inhibited and Ang II action is diminished, leading e.g. to
vasorelaxation (Kööbi et al. 2003). On the other hand, they have no affinity to
AT2 receptors, but they have reported to exhibit high protein binding rates in
plasma (Carretero and Oparil, 2000b; Burnier 2001). The advantage of ARBs is
their good antihypertensive effect with minor adverse effects.
2.1.6 Bioactive tripeptides
In addition to the ACE inhibitors and ARBs, accumulating evidence would
indicate that small bioactive peptides, e.g. casein-derived peptides have
positive cardiovascular effects even when added to food (Jauhiainen and
Korpela 2007; Möller et al. 2008; Erdmann et al. 2008). According to animal
(Jauhiainen et al. 2005a) and human (Jauhiainen et al. 2005b) studies long-
term oral treatment with milk products containing small tripeptides has lowered
blood pressure and reduced arterial stiffness in hypertensive patients.
Investigations have focused especially on tripeptides containing amino acids Ile-
Pro-Pro (IPP), Val-Pro-Pro (VPP) and Leu-Pro-Pro (LPP);  for  molecule
REVIEW OF THE LITERATURE
24
structures, see Figure 2. IPP has been shown to have most powerful effects on
blood pressure. The antihypertensive mechanism of bioactive peptides is not
exactly known but it has been surmised to be related to inhibition of ACE, but
also to calcium, potassium and magnesium metabolism (Hong et al. 2008).
IPP
LPP
VPP
Figure 2. Molecule structures of bioactive tripeptides (Bachem Distribution
Services GmbH).
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2.2 TISSUE RENIN-ANGIOTENSIN SYSTEM
In addition to the circulatory RAS there is a tissue-localized system which has
been known for some time and which is seen to regulate long-term changes in a
variety of organs (Metsärinne et al. 1996; Bader et al. 2001). In the other words,
RAS is not only endocrine but also complicated autocrine system. In tissues
Ang II is derived either from the circulation, or from its local production. Local
Ang II formation can also be catalyzed by enzymes other than the classical
ACE, actions termed renin-independent or ACE-independent pathways for Ang
II production (Kramkowski et al. 2006). By blocking the activity of these
enzymes Ang II production can be reduced. In addition to ACE- independent
enzymes, there is an important recently discovered RAS component:
angiotensin-converting enzyme 2 (ACE2). ACE2 can degrade Ang I to Ang (1-9)
and Ang II to form the biologically active Ang (1-7), which in turn acts in many
respects opposite to Ang II. According to the literature these alternative
pathways for Ang II production and for degradation of Ang II are important in
both physiological and pathophysiological conditions (Urata et al.1990; Bacani
and Frishman 2006).
2.2.1 Alternative pathways for Ang II production
Chymostatin-sensitive Ang II generating enzyme (CAGE)-dependent
pathway of Ang II production
CAGE is a protease able to convert Ang  I to Ang II.  It  is  found  e.g.  in  the
human, monkey and dog aorta, distributed predominantly in the adventitia, while
ACE is found localized mainly in the endothelium. Such a contrasting
distribution may indicate the distinct functional role of these two enzymes. The
exact role of CAGE in physiology is yet unknown (Okunishi et al. 1987;
Kramkowski et al. 2006).
Chymase-dependent pathway of Ang II production
Chymases (?- and ?-chymase) are chymotrypsin-like serine proteases found in
the heart, kidney, vascular smooth muscle and secretory granules of mast cells.
They are able to cleave Ang I to produce Ang II, but not to form Ang II direct
from angiotensinogen (Urata et al. 1990; Miyazaki and Takai 2006). Chymase-
mediated Ang II production may have an important role especially in
pathological conditions (Bacani and Frishman 2006). Chymase may be
REVIEW OF THE LITERATURE
26
associated with the development of diabetic and hypertensive nephropathy
(Huang et al. 2003), vascular proliferative diseases (Nishimoto et al. 2001) and
myocardial infarction (Jin et al. 2002).
Cathepsin G-dependent pathway of Ang II production
Membrane-bound cathepsin G expressed on neutrophils is a serine protease
able to convert Ang  I to Ang II,  but  also  to  produce Ang II direct  from
angiotensinogen (Klickstein et al. 1982; Belova 2000).  Cathepsin G may evince
potent local vasoactive and chemoattractant properties in inflammation (Owen
and Campbell 1998). An other serine protease, called tonin (Grisé et al.1981),
as well as the tissue-type plasminogen activator, trypsin and chymotrypsin, are
also able to release Ang II directly from angiotensinogen (Kokkonen at al.
1998).
2.2.2 ACE 2 dependent pathway of Ang II metabolism
Angiotensin-converting enzyme 2 (ACE2)
The human angiotensin-converting enzyme-related carboxypeptidase (ACE2) is
a structurally related homolog of ACE with 42% protein sequence identity
(Donoghue et al. 2000; Vickers et al. 2002), but it acts contrary to  the
carboxypeptidases, and increases Ang  (1-9) and Ang (1-7) formation. Unlike
ACE, ACE2 is not able to degrade bradykinin. ACE2 is mainly expressed in
cardiac blood vessels, kidneys and testis (Tipnis et al. 2000). It is considered to
be a balancing counter-regulator in the RAS, as it is able to convert especially
the bioactive Ang II to form vasorelaxing Ang (1-7) with high affinity, and Ang I
to form Ang (1-9), which in turn serves as a substrate for the generation of Ang
(1-7) (Donoghue et al. 2000; Mustafa et al. 2001). It is of importance in that both
Ang (1-7) and Ang (1-9) have physiological effects opposite to those of Ang II.
In the absence of ACE2, the predominant effects of Ang II lead  to
vasoconstriction and hypertension. In the light of such findings, ACE2 can be
regarded as an important modulator of blood pressure (Yagil and Yagil 2003).
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2.2.3 Ocular RAS expression
RAS in ocular tissues has also been under investigation during recent years.
Most of the recognized RAS components have already been detected in the
human eye (Danser at al. 1994; Wagner et al. 1996), except for the recently
described Mas receptor for Ang (1-7) and novel peptidases degrading
angiotensins. Prorenin, the precursor of renin, has been identified in the human
ciliary body responsible for aqueous humor formation (Sramek et al. 1988).
Renin mRNA has been detected in the retinal pigment epithelium and choroid
(Wagner et al. 1996). Angiotensinogen has also been found in the non-
pigmented epithelial cells (NPEC) of ciliary body (Sramek et al. 1992), and its
gene expression has been demonstrated in the retina, choroid and sclera
(Wagner et al. 1996). Ang I has been found in aqueous humor (Danser et al.
1994) and Ang II in many human ocular tissues: in the NPEC, in cells of the
cornea, in epithelial cells of the conjunctiva, in trabecular meshwork (TM) cells
as well as in ganglion cells, and photoreceptor cells of the retina, in addition to
endothelial cells in retinal and choroid vessels (Savaskan et al. 2004). ACE has
been identified in the human NPEC but also in the retina and choroid (Savaskan
et al. 2004). ACE has also been found in the human tear fluid (Immonen et al.
1987). ACE2 has been localized in M?ller cells and photoreceptors in the retina
(Tikellis et al. 2004) and Ang (1-7) has very recently been found in the human
retina (Senanayake et al. 2007). Ang II receptors (predominantly type 1) are
present in the retina, e.g. in M?ller cells and blood vessels (Senanayake et al.
2007) and in ganglion cells as well as in the cornea (Savaskan et al. 2004). AT2
receptors are also localized in M?ller cells, in ganglion cells and in the inner
nuclear layer of the retina (Senanayake et al. 2007). For details, see Table 1.
Expression of ocular RAS has also been investigated in several animal studies.
For details, see Table 1.
Table 1. Localization of RAS components in ocular tissues of different species
(Vaajanen et al. 2008).
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RAS molecule Eye part Species References
Retina Human Sramek et al., 1988
Ciliary body Human Danser et al., 1989
Prorenin
Vitreous body Human
Retina Human, rabbit Danser et al., 1989
Ciliary body Rabbit Wagner et al., 1996
Choroid Human, rabbit Ramirez et al., 1996
Iris Rabbit
Vitreous body Human, rabbit
Renin
Aqueous humor Rabbit
Retina Human, rabbit Sramek et al., 1992
Ciliary body Human, rabbit Ramirez et al., 1996
Choroid Human, rabbit Wagner et al., 1996
Iris Human, rabbit
Vitreous body Human, rabbit
Angiotensinogen
Aqueous humor Rabbit
Retina Dog, monkey, human, Vita et al., 1981
rabbit, porcine Weinreb et al., 1985
Ciliary body Human, rabbit, porcine Immonen et al., 1987
Choroid Dog, monkey, human, Ramirez et al., 1996
rabbit, porcine Wagner et al., 1996
Sclera Dog, monkey Shiota et al., 1997
Iris Rabbit, porcine Geng et al., 2003
Cornea Human Savaskan et al., 2004
Vitreous body Dog, monkey, rabbit
Aqueous humor Human, dog, monkey, rabbit
ACE1
Tear fluid Human, rabbit
Rodent Tikellis et al., 2004ACE2 Retina
Human Senanayake et al., 2007
Choroid Dog Shiota et al., 1997
Sclera Dog Maruichi et al., 2004
Chymase
Vitreous body Human
Retina Human Savaskan et al., 2004Ang II receptor
type 1 Cornea Human Senanayake et al., 2007
Ang II receptor
type 2
Retina Human Senanayake et al., 2007
Retina Porcine
Choroid Porcine
Vitreous body Porcine, human
Ang I
Aqueous humor Human
Danser et al., 1994
Retina Human, porcine, rabbit Danser et al., 1994
Ciliary body Human, rabbit Ramirez et al., 1996
Choroid Porcine, human, rabbit Savaskan et al., 2004
Iris Rabbit Senanayake et al., 2007
Cornea Human
Vitreous body Porcine, human, rabbit
Ang II
Aqueous humor Human, rabbit
Ang 1-7 Retina Human Senanayake et al., 2007
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2.3 INTRAOCULAR PRESSURE
The average volume of the adult human eye globe is about 6.5 cm3 and the
average globe dimensions are 24 mm (anterior-posterior), 23 mm (vertical) and
23.5 mm (horizontal). The vitreous body comprises about 80 % and aqueous
humor (AH) 20 % of the globe volume (Sherman et al. 2006). In the healthy
human eye, the flow of AH against resistance generates an IOP of about 15
mmHg, which is necessary for the proper shape. The circulating AH nourishes
unvascularized eye structures such as the cornea and lens and it has an
important role in the optical system (Brubaker 1982; Millar et al. 2006). IOP is
maintained by a homeostatic balance between formation and outflow of AH. For
anatomy and AH pathway, see Figure 3.
2.3.1 Aqueous humor formation
AH is secreted by the ciliary epithelium lining the ciliary processes mainly by
active ionic transport across the epithelium against a concentration gradient.
(Hoy and Delamere 2002; Millar et al. 2006). The anatomy of the ciliary process
is depicted in Figure 4.  Active secretion requires energy, normally provided by
the hydrolysis of adenosine triphosphate by Na+/K+ ATPase (Caprioli 1992).
Energy-dependent active transport of sodium into the posterior chamber by the
non-pigmented ciliary epithelial cells (NPEC) results in water movement from
the stromal pool into the posterior chamber. Active transport of Cl- and HCO-3
(formed in the reaction sequence catalyzed by carbonic anhydrase) occurs to a
lesser extent (Caprioli 1992). In addition to active secretion there are two
essential physiological processes in the formation of AH: diffusion from the
blood compartment and ultrafiltration. These two processes are passive and
require no active cellular participation. Diffusion of solutes across cell
membranes occurs down a concentration gradient, and substances with high
lipid solubility coefficients which can easily penetrate biological membranes
move readily in this way. Ultrafiltration is the term used to describe the bulk flow
of blood plasma across the fenestrated ciliary capillary endothelia into the ciliary
stroma; it can be increased by augmentation of the hydrostatic driving force
(Millar et al. 2006).  Recent findings such as the discovery of anti-angiogenic
factors in the human ciliary body may open up new prospects for an
understanding of AH secretion, IOP and the progression of glaucoma. The
ciliary body should be regarded as a multifunctional and interactive tissue
(Coca-Prados and Escribano 2007).
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The AH formation rate in the healthy human eye is 2.5-2.8 µl/min and the entire
volume is replaced every 100 min. It is known to reduce in certain
circumstances: during sleep, with ageing and in some systemic diseases such
as diabetes (Brubaker 1991). There is a circadian rhythm of flow, with the
highest rate during morning hours and the lowest during night hours especially
in a sleep. The nighttime reduction of AH flow has been reported to be even
45% (Reiss et al. 1984), but the suppression of flow is greater than the change
of intraocular pressure (Ericson 1958). On the other hand, IOP depends on the
body position: it is higher in head - down vs. head - up position while aqueous
flow is same in both body positions (Carlson et al. 1987). AH formation is almost
stable up to the age of 60, but thereafter it decreases with advancing age
(Becker 1958). A slight decline of flow rate occurs after even age 10, about 3 %
per decade (Brubaker 1981). In addition, there has been reported to be a
tendency toward less AH formation eg. in the advanced stages of diabetic
retinopathy (Larsson et al. 1995).
Under normal conditions active secretion accounts for 80% to 90% of total AH
formation (Weitzman and Caprioli 2006). Active secretion is essentially
pressure-insensitive at near-physiological IOP. However, the ultrafiltration
component in AH formation is sensitive to changes in IOP, decreasing as this
increases. This phenomenon is quantifiable and is termed pseudofacility,
because a pressure-induced decrease in inflow appears as an increase in
outflow when techniques such as constant-pressure perfusion are used to
measure outflow facility (Bàrany 1963; Beneyto et al. 1995). From the posterior
chamber AH flows around the lens and through the pupil into the anterior
chamber, from which it leaves the eye through two main pathways at the
anterior chamber angle.
2.3.2 Aqueous humor drainage
AH exits the eye principally through the trabecular meshwork in the chamber
angle and Schlemm's canal into the aqueous veins. This is called trabecular or
conventional outflow (Lütjen-Drecoll et al. 2001). The state of the actin
cytoskeleton and adhesions of trabecular meshwork cells are important
determinants of fluid outflow through the trabecular meshwork (Tan et al. 2006).
On the other hand, fluid flow through the inner wall endothelium of Schlemm's
canal is controlled by the location of the giant vacuoles and pores present in
cells of the endothelium, but the flow resistance itself is more likely to be
generated either in the extracellular matrix of the juxtacanalicular connective
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tissue or the basement membrane (Johnson 2006). A smaller proportion of AH
makes its way directly into the ciliary body and is drained by way of the ciliary
muscle, the suprachoroidal space, and the sclera, a process termed uveoscleral
or unconventional outflow (Lütjen-Drecoll et al. 2001). In addition there is an
uveo-vortex route for AH drainage ie. a route via the iris blood vessels and the
vessels of ciliary muscle draining to the vortex veins. AH can also move by bulk
flow to the suprachoroidal space from which it is picked up by the choroidal
blood supply concerned with drainage of the anterior uvea and reaches the
vortex veins (Green et al. 1977). The main route (90%) of drainage in the
normal eye is that through the trabecular meshwork. This outflow channel is
pressure-dependent (Millar et al. 2006). Uveoscleral outflow constitutes
approximately 10% of total outflow, and it is virtually independent of IOP levels
greater than 7 to 10 mmHg. The other alternative, albeit minor, pathways of
outflow are those through iris vessels, corneal endothelium or anterior vitreous
body (Weinreb 2000).
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Figure 3. Anatomy of the human eye and aqueous humor pathway.
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Figure 4. Anatomy of ciliary process.
2.3.3 Goldmann`s equation
As noted above, IOP is maintained by a homeostatic balance between
formation and outflow of AH. The tissues of the anterior chamber angle offer a
resistance to fluid outflow. IOP builds up, in response to the inflow of AH, to a
level sufficient to drive fluid across that resistance at the same rate as it is
produced by the ciliary body. This is the steady-state IOP. In the glaucomatous
eye this resistance is unusually high, causing elevated IOP (Millar et al. 2006).
Goldmann`s equation has served for over 50 years as an adequate description
of aqueous humor dynamics (Goldmann 1951; Brubaker 2004).
F=(Pi - Pe) X C
F= the rate of aqueous humor formation
Pi= intraocular pressure
Pe= episcleral venous pressure
C= tonographic facility of outflow
REVIEW OF THE LITERATURE
34
2.3.4 Regulation of intraocular pressure
The precise mechanisms in the regulation of IOP as well as underlying reasons
for glaucomatous optic nerve damage are not known. The autonomic nervous
system may have a major role in the regulation of IOP by reason of the
existence and function of its receptors for the relevant structures involved in AH
formation (Ruskell 1982) and drainage (Millar et al. 2006).  In addition to IOP,
ocular perfusion instability and vascular dysregulation are both contributed to
glaucomatous optic neuropathy. The main cause of the perfusion instability is a
disturbed autoregulation in the context of a general vascular dysregulation
which can be caused by dysfunction of autonomic nervous sytem and vascular
endothelial cells (Gherghel et al. 2004; Grieshaber and Flammer 2005).
Circulation and blood pressure are partly regulated by the autonomic nervous
system but also by RAS, which acts via vasoconstriction but also via body
sodium and fluid balance mechanisms (Jackson 2006). Thus local RAS may be
the other major player in the regulation of IOP, the mechanism of action being
involved more probably in the formation of aqueous humor, but also having a
role in its drainage.
Autonomic nervous system
In general, parasympathomimetics (cholinergic drugs) acting via muscarine
receptors cause vasodilation in the anterior segment, resulting in increased
blood flow to the choroid, iris, ciliary processes and ciliary muscle (Sato  and
Sato 1995; Barbelivien 1995). Opinions vary as to the direct influence of
cholinergics on AH formation but their IOP-lowering effects are assumed to be
mediated by a decrease in the resistance in aqueous outflow. The action is
mediated entirely by ciliary muscle contraction and alteration in the trabecular
meshwork configuration, leading to reduced resistance to AH outflow with no
direct pharmacological effect on the trabeculat meshwork itself (Kaufman and
Bárány 1976). Parasympathomimetics are also reported to diminish drainage
through the uveoscleral route (Weitzman and Caprioli 2006).
Sympathetic (adrenergic) drugs act via ?1,  ?2,  ?1 or  ?2 receptors, which have
opposite actions. Activation of ? receptors by sympathomimetics improves AH
outflow and probably also its formation, while inhibition of ? receptors by
sympathetic receptor blockers reduces AH formation, both actions leading to
reduced IOP. Timolol, one of the most effective antiglaucomatous agents, acts
via non-selective ?-receptor blocking (Zimmerman et al. 1977; Yablonski et al.
1978) Sympathominetics affect smooth-muscle tone in the iris and ciliary body
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and their receptor stimulation may alter intraocular, intrascleral and extrascleral
vascular tone, while also having possible direct effects on the endothelium lining
the outflow pathways, all of which may alter total outflow facility (Townsed and
Brubaker 1980; Millar et al. 2006).
Other mechanisms
Several other mechanisms may be involved in the regulation of IOP:
serotonergic (Krootila et al. 1987), dopaminergic (Siegel et al. 1987),
adenosinergic (Crosson 1995), and prostaglandinergic (Camras et al. 1996) as
well as  corticosteroid- and glycosaminoglycans-mediated mechanisms (Millar
et al. 2006, Coca-Prados and Escribano 2007).
The prostaglandin mechanism may be one of most important ones in that
exogenous prostaglandin analogues are among the most potent
antiglaucomatous drugs. They enhance uveoscleral outflow (Weitzman and
Caprioli 2006). Endogenous prostaglandins may be involved in low IOP in eye
inflammation processes (Goldstein and Tessle 2006). The corticosteroid
mechanism is also clinically important, since topical or systemic glucocorticoids
may induce elevation of IOP in susceptible individuals (Yamamoto et al. 2008).
2.3.5 Glaucoma
Definition
Glaucoma is a multifactorial long-term ocular neuropathy which is associated
with a progressive loss of the visual field, retinal nerve fiber structural
abnormalities and optic disc changes (Bathija et al. 1998; McKinnon et al.
2008). Normal (mean ± SD) IOP is 15.5 (±2.57) mmHg, but due to a gaussian
distribution in which two standard deviations include the values of about 95% of
the population, an IOP over 20.5 (±2) mmHg could be considered as upper limit
for normal IOP. Before settling on a glaucoma diagnosis in patients with
elevated IOP, it is essential that characteristic optic nerve head cupping or
visual field abnormalities have appeared, otherwise high IOP is to be regarded
as ocular hypertension (Kwon and Caprioli 2006). Optic nerve cupping
(=excavation) means that the nerve head cup:disc ratio is 0.5 or greater. Also a
difference in cup: disc ratio of 0.2 or more between the right and left eye is a
pathognomic disturbance caused by glaucoma (Dielemans et al. 1994). Other
signs attributable to glaucoma are increased pallor of the nerve head, changes
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in vessels, splinter hemorrhage, peripapillary atrophy and retinal nerve fiber
layer defects (Infeld and O`Shea 1998). On the other hand, a glaucoma
diagnosis can be reached even in ocularly normotensive patients if optic nerve
cupping or typical visual field defects are manifested. This situation is seen in
low-tension ie. normotensive glaucoma eyes (Grosskreutz and Netland 1994).
Primary open-angle glaucoma is usually a symptomless and progressive illness
which if left untreated leads to visual disability and eventual blindness (Weinreb
and Khaw 2004).
Epidemiology and risk factors
Worldwide glaucoma is the second leading cause of blindness after cataract
(Weinreb and Khaw 2004). Incidence data on true glaucoma are limited;
according to the population-based Barbados Incidence Study of Eye Diseases
(1992-1997, n=3427), the observed four-year incidence of open-angle
glaucoma was 1.2 % (95% CI: 0.6, 2.1%), being highest in elderly persons (70
or more years) 4.2% (95% CI: 2.6, 6.3%) (Wu et al 2001). There will be 60.5
million people with glaucoma in 2010, increasing to 79.6 million by 2020, and of
these, 74% will have OAG.  Asians will represent 47% of those with a glaucoma
diagnosis, and with angle-closure glaucoma even up to 87%. Bilateral blindness
will be present in 4.5 million people with OAG in 2010, rising to 5.9 million
people in 2020 (Quigley and Broman 2006). A major modifiable risk factor for
glaucoma is (elevated) IOP, others including increasing age, black race, male
sex, positive family history (Sommer 1996; Deva et al. 2008) and in addition
lean body mass and a cataract history (Leske et al. 1995). Factors considered
as minor, are myopia, diabetes mellitus, systemic hypertension (Bonomi et al.
2000), migraine / vasospasms and vascular dysfunction (Tielsch et al. 1995;
Grieshaber and Flammer 2005).
Pathogenesis
There are several theories with respect to the pathogenesis of glaucoma
diseases, but the precise mechanism of POAG is unknown. The mechanical
theory envisages direct pressure-induced damage to the retinal ganglion cell
axons at the level of the lamina cribrosa. The vascular theory proposes
microvascular changes and resultant ischemia in the optic nerve head. Cellular
and molecular events conceivably leading to glaucomatous retinal ganglion cell
death have also been proposed in the pathogenesis of glaucoma (Kwon and
Caprioli 2006). It may be concluded that although elevated IOP is the major
known risk factor for glaucoma, the condition is linked at least to altered ocular
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blood flow; fluctuations in blood flow are more harmful in glaucomatous optic
neuropathy than a steady reduction in ocular blood flow (Tielsch et al. 1995;
Grieshaber and Flammer 2005). In addition, e.g. fluctuations in systemic blood
pressure (episodic nocturnal hypotension) can increase the susceptibility of the
optic nerve head to damage (Mitchell et al. 2004).
Table 2. Classification of glaucoma subtypes according to Duane`s
Ophthalmology (2006).
A Developmental glaucoma
1. Primary congenital glaucoma
2. Glaucoma associated with congenital anomalies
3. Secondary glaucoma in infants
B Primary open-angle glaucoma
1.Primary open-angle glaucoma
2.Ocular hypertension
3.Normotensive glaucoma
C Primary angle-closure glaucoma
1.Pupillary block glaucoma
2.Plateau iris
3.Ciliary block glaucoma (malignant glaucoma)
D Lens-related glaucoma
E Exfoliative glaucoma
F Pigmentary glaucoma
G Glaucoma following trauma
H Uveitic glaucoma
I Corticosteroid-induced glaucoma
J Glaucoma associated with retinal disorders
K Glaucoma associated with corneal disorders
L Glaucoma in aphakia and pseudophakia
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Glaucoma subtypes
The glaucoma diagnosis comprises heterogeneous groups of diseases causing
elevated IOP or typical ocular damage, and it can be divided into subtypes
according to its etiology, pathophysiological mechanisms or anatomical
properties. One mode of classification is shown in Table 2. Primary open-angle
glaucoma is the most common form (McKinnon et al. 2008). On the other hand,
up to 50% of POAG patients have normal IOP and thus so-called normotensive
glaucoma (Tielsch et al. 1991; Grosskreutz and Netland 1994).
Current pharmacotherapy
All therapies currently used for the treatment of glaucoma are aimed at lowering
IOP or preventing a rise in IOP in order to minimize cell death. Therapeutic
agents under wide investigation are neuroprotectants, which target the disease
process manifested in the death of retinal ganglion cells, axonal loss and
irreversible loss of vision (Khaw et al. 2004; McKinnon et al. 2008). A reduction
in IOP by 30% reduces disease progression from about 10% to 35%, even in
normotensive glaucoma patients (Tielsch et al. 1995; Bonomi et al. 2000). The
target IOP level in the treatment of glaucomatous eyes is about 25% to 30%
lower than the baseline pressure before treatment, or even greater if there is
substantial damage in the visual field (Jampel 1997). Current pharmacotherapy
comprises drugs acting on adrenergic ? - and ?- receptors or on cholinergic
muscarine receptors, prostaglandin analogues and carbonic anhydrase
inhibitors and combinations of these compounds (Vapaatalo 1995; McGinnon et
al. 2008). They are administered mainly topically and targeted either to reduce
the formation of aqueous humor in the ciliary body or to increase outflow
through uveoscleral pathways (Table 3).
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Table 3. Effects of ocular hypotensive agents on intraocular pressure and aqueous humor
dynamics  (Weitzman and Caprioli 2006).
Compound IOP Aqueous Conventional Uveoscleral
production outflow facility outflow facility
Non-selective ?-blocker ?? 20%-30% ? 35%
?1 selective ?-blocker ? 15%-25% ? 25%
Direct miotic ? 15%-25% ? 25% ?
Non-selective adrenergic
agonist ? 15%-25% ? ?
?2-agonist ? 20%-30% ? 35% ?
Carbonic anhydrase inhibitor ? 20%-35% ? 35%
Prostaglandin analogue ? 25%-35% ? 100%
Blood-ocular barriers
Blood-ocular barriers are important in protecting the eyes as is the blood-brain
barrier in protecting the brain i.e. compartments in the systemic circulation have
to penetrate blood-ocular barriers in order to penetrate the eye, which can occur
at least if the barriers are broken. This is also important in respect of systemic
RAS and drug penetration from the circulation into the eye structures. Two
blood-ocular barriers are clinically significant: the blood-retina barrier (BRB) and
the blood-aqueous barrier (BAB). The BRB may be seen to comprise two major
components: the endothelium of retinal blood vessels (inner barrier) and the
retinal pigment epithelium (outer barrier) (Cunha-Vaz 2004). The BAB is formed
by an epithelial barrier located in the non-pigmented layer of the ciliary
epithelium and in the posterior iridial epithelium, and by the endothelium of the
iridial vessels (Cunha-Vaz 1979).
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2.3.6 Relationship between BP and IOP
A number of human studies have been carried out on the relationship between
ocular hypertension or glaucoma damage and systemic hypertension, but no
clear consensus prevails as to whether IOP is related to the level of BP. There
seems to be no relation between systemic and ocular hypertension (Tarkkanen
et al. 2008). On the other hand, in some studies BP has been described as
having a modest positive association with POAG or IOP (Tielsch et al. 1995;
Bonomi et al. 2000). Particularly, poorly controlled hypertension seems to be
related to a modestly increased risk of OAG, but independently of the effect of
BP on IOP and other glaucoma risk factors (Mitchel et al. 2004). Low systemic
BP has been found to be associated with reduced IOP (Klein et al. 2005), and
arterial hypertension has been associated with increased IOP and high tension
glaucoma (Dielemans et al. 1994). On the other hand, observations to the
contrary have also been reported (Leske et al. 1995; Sommer et al. 1996).
2.3.7 Functional intraocular RAS
There is as yet only limited evidence regarding the role of the RAS in aqueous
humor outflow, but Ang II has been reported to be able to induce cell
proliferation in bovine trabecular meshwork cells and increase the synthesis of
collagen in vitro (Shen et al. 2001). It has been reported that Ang II
administered intracamerally diminishes uveoscleral outflow (Inoue et al. 2001b).
On the other hand, synthetic and natural Ang II has been reported to reduce
IOP in in vivo studies with anesthetized cats when administered intravenously
(Macri et al. 1965). The same IOP-lowering effect has been seen in the
enucleated, arterially perfused cat and human eye, the mechanism behind the
effect being considered to consist in vasoconstriction of the iris artery. In recent
human studies orally administerd losartan (ARB) (Costagliola et al. 2000) and
captopril, an angiotensin-converting enzyme (ACE) inhibitor (Costagliola et al.
1995) have been shown to lower IOP even when administered orally. Topical
application of olmesartan (ARB) (Inoue et al. 2001b; Wang et al. 2005),
inhibitors of ACE (Watkins et al. 1987; Shah et al. 2000) and renin (Giardina
1990) has been reported to lower IOP in animal studies, the effect being more
prominent in ocular-hypertensive animals (Inoue et al. 2001b;  Wang et al.
2005a).
Taken together, expression of intraocular RAS has been demonstrated in a
number of studies and it is involved in the regulation of IOP, being probably
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more activated in glaucomatous eyes, the exact mechanism of action is
remaining however unclear.
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3 AIMS OF THE STUDY
Renin-angiotensin system (RAS) is an important regulator of blood pressure
and body fluid homeostatic balance. Evidence is accumulating to indicate its
importance also for local intraocular regulating systems. The aim of the present
study was to investigate the expression of renin-angiotensin system in the
different eye structures and its function in the regulation of IOP. Rabbits and
rats were used as experimental animals for in vivo studies, and enucleated eyes
of rats and pigs were used for in vitro studies.
The specific aims were:
1. To investigate RAS expression and function in the various ocular tissues
(Studies I-III).
2. To compare the ocular hypotensive effects of different components of
RAS using local (Study III) and systemic administration in ocular
normotensive animals (Study IV).
3. To test whether the IOP-lowering mechanisms of angiotensins are
related to changes in aqueous humor outflow facility (Study III).
4. To clarify the potential relationship between blood pressure and
intraocular pressure in an experimental study (Study IV).
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4 MATERIALS AND METHODS
4.1 EXPERIMENTAL ANIMALS AND TISSUES
In Studies I and IV the experimental animal strains comprised male
spontaneously hypertensive rats (SHR, n=16) together with their arterial
normotensive Wistar Kyoto controls (WKY, n=16), and male double transgenic
rats harboring human renin and human angiotensinogen genes (dTGR, n=35)
together with their normotensive control animals (Sprague-Dawley, SD, n=12).
The animals were kept at 22±1°C in a 12-h light-dark cycle (lights on 7 a.m. to 7
p.m.), relative humidity (40-70%) and ventilation (air volume change 20
times/h).  The animals were kept four to a cage, and had free access to a
standard laboratory diet and tap water. At the end of the in vivo study (Study IV)
the rats were euthanized with CO2/O2 (AGA, Riihimäki, Finland) and
decapitated. The eyes were immediately enucleated and snap-frozen for
subsequent in vitro analyses (Study I).
Male New Zealand White rabbits (NZW, n=38) were used in Study III. Animals
were housed in individual cages under a 12-h light-dark cycle (lights on 7 a.m.
to 7 p.m.), and maintained conventionally during the study with regulated air
temperature (15-21ºC), relative humidity (40-70%) and ventilation (air volume
change 20 times/h). They had free access to a standard laboratory diet and tap
water. At the end of the study the animals were euthanized by intravenous
pentobarbital injection (100 mg/kg), (Mebunat®, Orion Ltd, Finland).
Fresh enucleated porcine eyes (n=56) were obtained from a local abattoir and
from each eye three tissue samples were prepared for further enzyme activity
analysis (Study II).
4.2 BIOCHEMICAL DETERMINATIONS
4.2.1 Real-time quantitative reverse transcriptase-polymerase chain
reaction (RT- PCR) (I)
The rat eyes were enucleated immediately after sacrifice (Study IV), snap-
frozen in isopentane at -40°C and stored at -70°C for subsequent RT-PCR
analysis (Study I). The frozen eyes were embedded in OCTTM compound
(Tissue-Tec®,Sakura, Japan), cornea upwards, and 150 µm vertical sections of
the whole eye were cut using a cryostat (-19 ºC) (Figure 5.).  The presence of
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mRNA of AT1a, AT2 and Mas receptors was determined at the level of the ciliary
body and the level of the anterior retina without ciliary tissue. The effect
of oral antihypertensive treatment with Ang II receptor type 1 blocker on
receptor mRNA expression was evaluated.
Figure 5. A schematic illustration of the rat eye. Two vertical sections were used
for RT-PCR analysis: (A) level of ciliary body and (B) level of anterior retina.
Horizontal sections were used for quantitative in vitro autoradiography analysis
(C).
RNA extraction and cDNA synthesis
Total RNA was isolated from frozen tissue sections using Trizol reagent
according to the manufacturer`s instructions. The RNA concentration was
determined spectrophotometrically at 260 nm and the quality of RNA was
checked by gel electrophoresis. Reverse transcription of RNA was performed
by using M-MLV reverse transcriptase according to the manufacturer`s
instructions.
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Real-time quantitative RT-PCR
PCR reactions were assayed either with SYBR Green I chemistry (AT1a and
Mas) or Taqman chemistry (AT2) using the ABI PRISM 7000 sequence
detection system. The Taqman assay utilizes sequence-specific fluorogenic
oligonucleotide probes and the 5’-nuclease activity of the DNA polymerase,
whereas SYBR Green I is a fluorescent dye binding to double-stranded DNA.
As SYBR Green I allows detection of any double-stranded DNA, both specific
and non-specific, a melting curve analysis was included in each PCR run to
confirm the amplification of the specific PCR product only.
The following primer sequences were used: AT1a forward 5'-
GGCAGCCTCTGACTAAATGGC-3' and reverse 5'-
ACGGCTTTGCTTGGTTACTCC-3', AT2 forward 5'-
TGTCTGTCCTCATTGCCAACA-3', reverse 5'-TTCATTAAGGCAATCCCAGCA-
3' and probe 5'FAM-TCAGAACCATTGAATACTT-MGB, and Mas forward 5'-
TCATGTGTATTGACAGCGGAGAA-3' and reverse 5'-
CACTAACATGAGCGGAGTGAAGA-3'. PCR reactions for AT1a and Mas
receptors were performed in duplicate in a 25 ml final volume containing 1X
SYBR Green Master mix and 300 nM of primers. PCR reactions for AT2
receptor and housekeeping control gene 18S were performed in duplicate in a
25 ml final volume containing 1X TaqMan Master mix and 300 nM of AT2
receptor primers and 150 nM of AT2 probe, or 1X 18S TaqMan Gene
Expression Assay primer and probe mix. PCR cycling conditions were 10 min at
+95ºC and 40 cycles of 20 seconds at +95ºC and 1 min at +60ºC. .
Data were analysed using the absolute standard curve method as described in
the Applied Biosystems User Bulletin #2. Standard Curves were generated
using a dilution series of corresponding purified PCR products. The
amplification of a housekeeping gene18S was used for normalizing the
inefficiencies in cDNA synthesis and in the amount of RNA applied. Briefly, the
copy numbers of 18S were divided by the highest 18S value obtained in the
experiment, resulting in a correction factor for every sample. These correction
factors were then used to normalize the absolute copy numbers of each
receptor.  The normalized copy numbers were obtained by dividing the copy
numbers of AT1a, AT2, and Mas receptors by the corresponding correction
factors. The intra- and interassay coefficients of variation of the real-time PCR
method were < 2% and < 3.3% respectively (Gibson et al. 1996; Heid et
al.1996; Lakkisto et al. 2002).
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4.2.2 Quantitative in vitro autoradiography (I)
Autoradiography was performed using enucleated snap-frozen rat eyes from
Study  IV  as  in  RT-PCR  analysis.  Densities  of  AT1 and AT 2 receptors were
determined in the retina and in the ciliary body with the radioligand 125I-[Sar1-
Ile8]Ang II. The effect on receptor density of oral antihypertensive treatment with
ARB was evaluated.
The whole frozen eyes were embedded in OCTTM compound, the cornea facing
forward. Twenty-µm horizontal sections were cut through the ciliary body with a
cryostat at –19 ºC (Figure 5.). Each eye section was thaw-mounted on Super
Frost® Plus slides, dried, and stored at - 70 ºC. Iodination with 125I of [Sar1-
Ile8]Ang II was performed by the chloramine-T method, and the labelled
peptides were purified on SP-Sephadex C-25 columns. For AT1 receptor
autoradiography eye slices were preincubated for 15 min at room temperature
in 10 mM sodium phosphate buffer containing 150 mM NaCl, 5 mM Na2- EDTA,
0.2% bovine serum albumin (BSA), at pH 7.4, followed by one hour incubation
at 37 ºC in fresh volume of the same buffer containing 0.2 µCi/ml of 125I-[Sar1-
Ile8]AngII. Non-specific binding was determined in the presence of 1 µM
unlabelled Ang II. The density of AT1 receptors was determined from parallel
incubations with AT2 receptor antagonist PD123319, 10 µM final concentration,
while the density of AT2 receptors was measured in the presence of AT1
receptor antagonist losartan in the 10 µM final concentration. After incubation,
the sections were washed four times for one min in cold-buffer without BSA and
radioligand and then dried under stream of cool air.   The optical densities were
quantified by Image Gauge analysis system coupled to the FUJIFILM BAS-5000
photoimager. Receptor density was measured as mean pixels/square area from
five sections per eye; three squares from the retina and two squares from the
ciliary body (Zhuo et al. 1999; Stewen et al. 2003).
4.2.3 Fluorometric assay (II)
Fresh enucleated porcine eyes were kept on ice during transfer to the
laboratory and prepared under a microscope within five hours post mortem.
Each eye was dissected into vitreous mass, retina and ciliary body samples.
The respective tissue types from both eyes of the same animal were pooled in
preweighed plastic tubes. Each pooled sample (except for vitreous body
samples) was homogenized in 0.1 M disodium tetraborate buffer containing 0.3
M NaCl (pH 8.3) with a Silent Crusher S homogenizer for 20-30 sec. After
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homogenization the samples were deep-frozen at -80ºC for subsequent
analysis. For measurement of enzyme activities, homogenates were thawed
and centrifuged as instructed in the activity assay kits. Supernatants were
separated and used in measurement of enzyme activity by a sensitive
fluorometric assay (Friedland and Silverstein 1975).
ACE1 activity was determined from the amount of His-Leu formed by
enzymatic breakdown of synthetic substrate N-Hippuryl-His-Leu. Ten µl of
supernatant from the tissue sample or vitreous body as such was incubated for
60 min at +37ºC in a water bath with 125 µl of 10 mM substrate solution. In
order to obtain a sufficient reaction volume for the measurement procedure, 115
µl of 0.1 M disodium tetraborate buffer containing 0.3 M NaCl (pH 8.3) was
added to the reaction mixture to give a final substrate concentration of 5 mM.
After incubation the reaction was stopped by adding 1.5 ml 0.3 M NaOH.
Thereafter 100 µl of OPA (20 mg/ml in methanol) was added to the reaction,
followed by 10 min incubation, after which 200 µl of 3 M HCl was added to stop
the reaction. Finally the reaction mixtures were centrifuged at 3000 rpm for 10
min. The amount of fluorescent His-Leu liberated in the reaction was measured
fluorometrically, excitation wavelength 360 nm and emission wavelength 500
nm.  Each sample was assayed in duplicate and the mean was used in
calculations. Captopril, an ACE1 inhibitor, was included as control at a final
concentration of 1 µM in each measurement.
ACE2 activity was measured using the fluorescence-based commercial
SensoLyte™ 390 ACE2 Activity Assay Kit (AnaSpec), which is based on the use
of Mc-Ala/Dnp fluorescence resonance energy transfer (FRET) peptide as
substrate. ACE2 cleaves the substrate into two separate fragments and
fluorescence of Mc-Ala is monitored by fluorometer. The enzymatic activity of
ACE2 was measured according to manufacturer`s instructions. Each sample
was assayed in duplicate and the mean used in calculations. DX600, an ACE2
inhibitor, was included as control at a final concentration of 100 nM in each
measurement.
Enzymatic activities were characterized as micromoles of His-Leu formed (for
ACE1) and Mc-Ala (for ACE2) per minute. The enzyme activities in retina and
ciliary body were expressed as units/mg protein measured by Lowry´s method
(1951) and in the vitreous body as units per milliliter of sample. One unit (U) is
defined as the amount of enzyme required to release one µmol of reaction
product in one minute. The effects of the three tripeptides on ACE1 activity were
tested at concentrations from 1 to 330 µM, and ACE1 inhibition by captopril was
assayed at concentrations from 1 to 100 nM, while the effects of the three
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tripeptides on ACE2 activity were tested at concentrations from 1 to 10 mM, and
the ACE2 inhibition by DX600 was assayed at a final concentration of 100 nM.
The IC50 values were determined by regression analysis of enzyme inhibition
(%) vs inhibitor concentration.
4.3 PHYSIOLOGICAL MEASUREMENTS
4.3.1 Aqueous humor outflow measurement (III)
For outflow studies anesthesia was induced and maintained by intramuscular
injections of a combination of ketamine (Ketalar® 50 mg/ml, Parker-Davis
Warner Lambert Nordic AB, Solna, Sweden) and xylazine (Rompun®Vet 20
mg/ml, Bayer AG, Leverkusen, Germany). Intravenous indomethacin was given
at 10 mg/kg body weight (Confortid®, Dumex, Copenhagen, Denmark) before
the eye cannulation in order to minimize the effect of endogenous
prostaglandins. The test compounds and saline were injected into the vitreous 3
to 24 h before the outflow studies. When a specific antagonist was used, it was
administered 1 h before the test compound except olmesartan which was given
simultaneously with test compound. When the compounds were administered
direct into the anterior chamber, outflow was registered 30 min after
administration of the compounds.
The eyes of the animals were cannulated with three needles (27G) connected
to polyethylene cannulas. One cannula was used for continous IOP monitoring,
one for injection of the tes compound/vehicle and one for the infusion of fluid for
outflow facility measurements. The aqueous humor outflow facility was
measured with the constant pressure infusion method (Bárány 1964). IOP was
measured using pressure transducer P-50 (Gould/Statham, Bilthoven, The
Netherlands) and recorded by a Grass Model 79-D polygraph (Quincy, MA,
USA). A mock solution of aqueous humor was infused to the anterior chamber
from a reservoir until the IOP increased 5-7 mmHg above the preinfusion level
and the level of the reservoir was adjusted to give a steady state IOP. The
infusion rate (F1) and the increase in IOP (? P1) were registered over a 4-8 min
period in steady-state conditions. Thereafter the reservoir was elevated to give
a higher pressure (about 5-7 mmHg above the previous level and 10 to 14
mmHg above the preinfusion level), and the same procedure was repeated
under steady state conditions to obtain the values of the infusion rate (F2) and
the increase in IOP (?P2) above the preinfusion level. In order to constitute a
technically successful experiment, IOP had to return to the preinfusion level
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after the second infusion. The outflow facility could then be calculated from the
formula C=F/ ? P.
4.3.2 Intraocular pressure measurement (III,IV)
IOP of conscious rabbits (Study III) was measured with a pneumatonometer
(Modular One Tonometer, Mentor, Cambridge, MA, USA) after topical
anaesthesia of the cornea with 0.4 % oxybuprocain (Oftan Obucain®, Santen
Oy, Tampere, Finland). The pneumatonometer was calibrated for IOP
measurements in rabbits by simultaneous manometric and pneumatonometric
pressure measurement in cannulated eyes using the closed stopcock method
as described by Hammond and Bhattacherjee (1984). IOP was measured at 1h,
2h, 3h, 4h, 5 h and 6 h after administration of the test compounds except in the
case of Ang II when IOP was measured also at 12 h and 24 h. The basal IOP
for both eyes was always measured 1 h prior to the experiment.
The IOP of pre-trained conscious rats in Study IV was measured using a
specific rebound tonometer (TonoLab®, Tiolat Oy, Helsinki, Finland) after topical
anesthesia of the cornea with 0.4 % oxybuprocain (Oftan Obucain®, Santen Oy,
Tampere, Finland). The effect of general anesthesia on IOP was determined
using intraperitoneal injection (0.2 ml/100 g) of a 1:3 combination of ketamine
50 mg/ml and medetomidine hydrochloride (Domitor® 1 mg/ml, Orion Pharma,
Espoo, Finland).
4.3.3 Blood pressure measurement (III,IV)
Blood pressure in anesthetized rabbits (Study III) was measured by cannulating
a femoral artery with PE-50 polyethylene tubing containing heparinized isotonic
saline. The pressure was measured with a Statham P-50 pressure transducer
and recorded with a Grass Model 79 D polygraph. The blood pressure in pre-
trained conscious and anesthetised rats (Study IV) was measured using a tail-
cuff blood pressure analyzer (Apollo-2AB Blood Pressure Analyzer, Model 179–
2AB, IITC Life Science, Woodland Hills, CA, USA). The rats were prewarmed
for 15-20 min at +32ºC to improve detection of the pulsation of the tail artery.
The arithmetic mean of three successive measurements without disturbances of
the signal indicated the systolic blood pressure.
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4.4 TEST COMPOUNDS
Studies I and IV. The test compounds were Ang II receptor type 1 antagonists:
olmesartan medoximil (10 mg/kg/day, Olmetec®, Leiras, Turku, Finland) and
valsartan (30 mg/kg/day, Diovan®, Novartis, Basel, Switzerland).  Tablets were
ground and mixed in the food.
Study II. The test compounds were: IPP (isoleucyl-prolyl-proline), VPP (valyl-
prolyl-proline) and LPP (leucyl-prolyl-proline) purchased from Bachem, Weil am
Rhein, Germany. Positive control captopril, o-phthaldialdehyde (OPA), His-Leu,
purified ACE1 enzyme and N-Hippuryl-His-Leu hydrate (substrate) were
provided by Sigma-Aldrich (Schnelldorf, Germany). All compounds were
dissolved in disodium tetraborate buffer containing NaCl (pH 8.3), except that
OPA was dissolved in methanol. ACE2 activity assay kits, including all
necessary reagents, were purchased from AnaSpec (San Jose, CA, USA).
Study III. The compounds used were: human Ang II acetate (Sigma-Aldrich,
Schnelldorf, Germany), olmesartan (Daiichi Sankyo Co., Ltd., Japan), A-779
(GenScript Corporation, Piscataway, NJ, USA), and [Sar1Ile8] Ang II human,
CGP 42112A, PD 123319 and Ang (1-7) (purchased from NeoMPS,
Strassbourg, France). All compounds were dissolved in isotonic saline. The
fellow eye was treated with saline and served as a control in all experiments.
Dipivefrin hydrochloride (Propine®, Allergan, Mayo, Ireland) was used as a
positive control in topical administration.
Test compounds were given topically (1 to 3 gtt), intravitreally (50 µl) or
intracamerally (5µl).
4.5 STATISTICAL ANALYSES
The results are expressed as mean ± standard error of mean (SEM) in Studies
I-IV, and 95% confidence intervals (CI) in Studies III-IV. T-tests (Sigma Plot
Version 10.0) in Studies I-II or one-way analysis of variance (ANOVA) followed
by Dunnett´s post-hoc test (Study II) were used for statistical comparisons for
paired or unpaired data. Relationship between BP and IOP (Study IV) was
expressed using area under the curve (AUC), and statistical analysis between
and within groups by using t-test or permutation test (Stata Version 10.0).
?? 0.05 was considered statistically significant in all experiments.
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4.6 ETHICS
All animal procedures were in accordance with the ARVO Statement for the use
of Animals in Ophthalmic and Vision Research and with the Guide for the Care
and Use of Laboratory Animals, and the experiments were approved by the
National Animal Ethics Committee in Finland.
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5 RESULTS
5.1 RAS EXPRESSION
5.1.1 Angiotensin receptors in the eye tissue (I)
RT-PCR
The novel Mas receptor was found for the first time in the eye tissue in addition
to traditional AT1a and AT2 receptors. The mRNA expression of the Mas
receptor was lower than that of AT1a,  but  markedly  higher  than  that  of  AT2
receptors in every rat strain except in WKY rats. Angiotensin receptor
expression was overall more obvious in retina than in ciliary body. No direct
differences were seen between four rat strains, but ocular angiotensin receptor
expression was higher in dTGR compared to SHR. For receptor expressions,
see Table 4.
Oral treatment with ARB did not systematically influence the expression of
mRNA for Mas receptors, nor that of AT1a or AT2 receptors. Only the treated
SHR animals evinced slightly lowered expression of AT1a receptors vs.
normotensive controls in both tissues evaluated.
Autoradiography
The densities of AT1 and  AT2 receptors in the retina were more pronounced
compared to that in the ciliaris in every rat group in keeping with the results of
the RT-PCR analysis. The density of AT1 receptors was higher than that of AT2
receptors. There was seen no clear difference in receptor densities between
different rat strains (Table 5). Mas receptor could not been identified due to the
lacking methodology.
In contrast to the result obtained in RT-PCR analysis a clear difference was
seen between ARB-treated and non-treated animals in autoradiography
analysis. The apparent density of AT1 receptors in the retina in treated animals
was approximately 35% lower in SHR and SD rats and about 60% lower in
dTGR and WKY as compared to non-treated animals. This tendency was also
seen in the ciliary body. Medication with ARB did not systematically influence
the density of AT2 receptors, but medicated dTGR had more AT2 receptors
especially in the retina.
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Table 4. Expression of Mas, AT1a and AT2 receptors in arterial hypertensive rats
and their controls (for abbreviations, see text) in ocular tissues measured by RT-
PCR. Activity of ACE1 and ACE2 in porcine ocular tissues measured by
fluorometric assay. For RT-PCR: values (mRNA copies x 103/ng  total  RNA)  are
expressed as mean±SEM, n=4. NA= not assayed. For fluorometric assay: values
in retina and ciliary body are expressed as mean ± SEM mU/mg protein and in
the vitreous body mean ± SEM nmol/min/ml of sample, n=5-6.
The autoradiography results suggest that the density of AT1 receptors in the eye
is independent of the blood pressure level of the animals, but is influenced by
oral ARB treatment. Densities of AT1 and AT2 receptors and the respective
blood pressure values in individual animals are presented in Figure 6.
RAS component Retina Ciliary body Vitreous body
RT-PCR
Mas SHR 4.7±2.3 1.2±0.3 NA
WKY 6.5±3.6 3.8±1.6 NA
dTGR 11.1±1.3 1.3±0.1 NA
SD 9.6±3.3 2.5±1.1 NA
AT1a SHR 6.6±3.2 2.9±1.0 NA
WKY 10.2±6.2 6.4±2.2 NA
dTGR 16.5±1.9 2.1±0.4 NA
SD 15.8±5.6 3.2±0.4 NA
AT2 SHR 3.2±1.2 0.5±0.1 NA
WKY 7.3±3.3 2.1±1.0 NA
dTGR 6.4±0.5 0.3±0.0 NA
SD 6.0±1.9 0.4±0.2 NA
FLUOROMETRIC
ASSAY
ACE1 0.2±0.02 3.7±0.70 8.2±0.31
ACE2 0.2±0.01 0.2±0.02 0.1±0.02
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Table 5. Density of AT1 and AT2 receptors in the ocular tissues of arterial hypertensive
rats and their normotensive controls expressed as mean±SEM, n=4. Medicated= oral
treatment with ARB. For abbreviations, see text.
RAS-
component Retina Ciliary body
Non-medicated Medicated Non-medicated Medicated
AT1 SHR 3.6±1.1 2.5±0.5 2.3±0.6 1.2±0.2
WKY 4.3±0.2 1.7±0.6 3.1±1.3 1.4±0.5
dTGR 5.0±0.9 1.7±0.4 2.4±0.9 1.9±0.8
SD 4.4±0.7 2.5±0.5 4.6±0.0 2.5±1.3
AT2 SHR 2.8±1.8 1.0±0.5 0.9±0.6 0.4±0.2
WKY 2.0±0.3 1.4±0.3 0.7±0.2 0.8±0.3
dTGR 0.8±0.3 2.3±0.3 0.2±0.1 0.5±0.3
SD 1.5±0.9 2.6±0.1 1.1±0.4 2.6±0.1
5.1.2 Angiotensin enzymes in the eye tissue (II)
Fluorometric assay
ACE1 activity was significantly higher in ciliary body compared to retina. The
activities of ACE1 and ACE2 were at the same level in the retina, whereas the
ACE1 activity in the ciliary and vitreous bodies was manifold compared to
ACE2. ACE2 activity was for the first time found to be existed in vitreous and
ciliary bodies in addition to its known retinal activity (Table 4).
Different concentrations of the bioactive tripeptides were tested, the aim being
to compare the inhibitory activity of ACE1 vs. that of ACE2. The tripeptides IPP,
VPP and LPP showed inhibition of ACE1 activity at micromolar concentrations
in all tissues studied, i.e. porcine retina, ciliary and vitreous bodies (IC50 9-25
µM), while for ACE2 inhibition was obtained first at millimolar concentrations
(IC50 4-22 mM). For the inhibitory effects of IPP, VPP and LPP on ACE1 activity
in the ciliary body, higher peptide concentrations were needed than in the two
other tissues. The same effect was seen with the positive control, captopril.
Captopril effectively inhibited ACE1 but not ACE2 activity in all tissues (IC50 5-
10 nM).
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Figure 6. Blood pressure (BP) and angiotensin receptor densities in
individual animals. Open circle = non-treated hypertensive rat, filled circle
= ARB-treated hypertensive rat, open triangle = non-treated normotensive
control, filled triangle = ARB- treated normotensive control.
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5.2 FUNCTIONAL RAS
The ocular effects of RAS components are summarized in Table 6.
5.2.1 Topically administered RAS components (III)
Topical administration of the test compounds had no effect on normal IOP in
rabbits during 6-h follow-up (24-h for Ang II), and they had no adverse effects
on the surface of the eye. Dipivefrin was used as positive control and it reduced
IOP maximally at 3 h from baseline, 19.5 mmHg to 12.2 mmHg.
5.2.2 Intraocularly administered RAS components (III)
Intravitreal administration
The major finding in Study III was the oculohypotensive effect of intravitreally
administered 1 mM Ang (1-7) (p=0.008) in ocular normotensive rabbits. Ang (1-
7) reduced IOP maximally at 2 to 3 h after its intravitreal injection. The IOP-
reducing effect of Ang (1-7) was inhibited by A-779 (a specific Mas receptor
antagonist) and partially by PD123,319 (an AT2 receptor antagonist). When
administered alone, these two receptor antagonists had no effect on IOP.
Intravitreally administered Ang (1-7) had no effect on outflow facility.
Olmesartan (an AT1 receptor antagonist) administered intravitreally did not
antagonize the Ang (1-7) lowering effect (p=0.03). It reduced IOP in both eyes;
there was no difference between the test and the saline-injected fellow eyes. To
study the effects of intravitreal injection per se eight rabbits received isotonic
saline 50 µl in both eyes without significant changes in IOP.
Ang II did not influence IOP at the various concentrations tested.
[Sar1Ile8]Ang II (an unspecific Ang II receptor ligand) tended to lower IOP
between 2 to 4 h vs. the control eye (p=0.12).
CGP42112A (an AT2 receptor agonist) had no significant effect on IOP at the
various concentrations tested. Intravitreally administered CGP42112A had  no
effect on outflow facility.
RESULTS
57
Table 6. The effects of RAS compounds on IOP and outflow facility in rabbits
after intravitreal, topical and intracameral administration of test agents and the
effects of oral ARB on IOP and BP in rats. Different concentrations were tested in
rabbits, the main founding being oculohypotensive 1 mM Ang (1-7) when
administered intravitreally (50µl). For details, see text. Intravitreally administered
Ang II caused dose- dependent rise in IOP (?/-). ? = enhance, ? = diminish, - = no
effect, NA = not assayed, olme = olmesartan. * p?0.05, ** p<0.005, *** p<0.001.
Compound IOP Outflow facility
Mechanism of action intravitreal topical intravitreal intracameral
Ang II AT1 agonist ?/- - NA ?***
Ang (1-7) Mas receptor agonist ?*** - - -
+olme AT1 antagonist ?* - NA NA
+ A-779
Mas receptor
antagonist - - NA NA
+PD123,319 AT2 antagonist ? - NA NA
CGP42112A AT2 agonist ? - - -
+olme  topic. AT1 antagonist ? NA NA NA
PD123,319            AT2 antagonist - - NA NA
A-779
Mas receptor
antagonist - - NA NA
Sar1Ile8 Ang II
Unspecific AT receptor
ligand ?*** - NA NA
Olmesartan AT1 antagonist ? - NA NA
+CGP42112A AT2 agonist NA - NA NA
NaCl Control - - NA NA
Dipivefrin
Control: adrenergic
agonist NA ?** NA NA
Oral treatment
(rat): IOP BP
Valsartan 30
mg/kg AT1 antagonist - ?***
Olmesartan 10
mg/kg AT1 antagonist - ?***
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Intracameral administration
Neither intracamerally administered Ang (1-7) nor CGP42112A had any effect
on the outflow facility, while Ang II reduced it dose-dependently.
5.2.3 Orally administered RAS components (IV)
IOP
Oral treatment with ARBs seemed to have a slight effect on normal IOP in
growing animals, while it abolished the development of hypertension in SHR
and dTGR. The mean baseline IOP in SHR (age 5 weeks) was 18.4 mmHg and
in dTGR (age 4 weeks) 30.7 mmHg. Baseline IOP in their age-matched control
groups were 15.8 mmHg (WKY) and 13.1 mmHg (SD). IOP in non-treated adult
SHR, WKY (age 13 weeks), dTGR and SD (age 7 weeks) was 22.4 mmHg,
18.3 mmHg, 19.4 mmHg and 13.5 mmHg. IOP in oral ARB-medicated adult
animals was 19.1 mmHg (SHR-M), 20.3 mmHg (WKY-M), 18.2 mmHg (dTGR-
M) and 12.0 mmHg (SD-M), respectively.
Blood pressure
Oral treatment with ARBs effectively abolished the development of hypertension
in SHR and dTGR. Systolic BP in non-treated adult SHR, WKY, dTGR and SD
was 183 mmHg, 102 mmHg, 205 mmHg and 106 mmHg, and that in ARB-
treated adult animals 100 mmHg, 59 mmHg, 107 mmHg and 95 mmHg,
respectively.
5.2.4 Relationship between IOP and BP (IV)
A slight positive relationship between IOP and developing BP was seen in SHR:
non-treated hypertensive rats had higher mean IOP vs. normotensive animals
(P=0.048). However, in dTGR, IOP was not directly associated with high BP.
The high baseline IOP was reduced during the two weeks` follow-up in non-
medicated and medicated rats, while BP remained high in untreated animals but
was well controlled in treated rats.
The baseline IOP in young SD rats declined age-dependently, being 23.2
mmHg at the age of 4 weeks, 21.5 mmHg at 5 weeks, 17.8 mmHg at 6 weeks
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and 14.0 mmHg at 7 weeks, indicating the lowering tendency accompanying
ageing. BP according to our experience does not change markedly during such
a short follow-up time.
5.2.5 The effect of general anesthesia on IOP
We show here that intraperitoneally induced ketamine/medetomidine
hydrochloride anesthesia reduces IOP by at least 30 % (WKY) or even more in
hypertensive (SHR) rats (Study IV). As similar findings were observed in ARB-
treated animals it is evident that IOP measurements should be made without
general anesthesia.
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6 DISCUSSION
A functional RAS has recently been demonstrated in the human eye in several
studies, and there is accumulating evidence that the widely used RAS
antagonizing antihypertensive drugs are also able to reduce IOP. Until now no
drugs acting on RAS are in use in ophthalmology, but they may emerge as
potential antiglaucomatous drugs in the future. The present study determined
the expression and density of angiotensin receptors in the various eye
structures using RT-PCR and in vitro autoradiography analysis. The most
important RAS enzyme activities and their inhibition by bioactive tripeptides
were described using a fluorometric assay method. In addition, the present
study clarified the effects of different exogenous compounds acting on RAS, on
normal IOP and aqueous humor outflow, as well as the relationship between
IOP and developing high BP in in vivo experiments.
The main finding in the present study was the oculohypotensive effect of
heptapeptide Ang (1-7). The result, obtained with ocular normotensive rabbits,
indicated that Ang (1-7) acts via its own receptor type. A specific Ang (1-7)
receptor, the Mas- receptor, was then described in the eye structures of rats, for
the first time in the literature. A third finding in the context of intraocular RAS
was the existence of ACE2 in vitreous and ciliary bodies in addition to the
previous finding of its retinal activity (Tikellis et al. 2004; Senanayake et al.
2007). ACE2 is an enzyme responsible for degrading angiotensins, e.g. Ang II
to vasorelaxing products (Tipnis et al. 2000; Vickers et al. 2002).
6.1 METHODOLOGICAL ASPECTS
This experimental study was carried out to obtain new knowledge regarding
intraocular RAS and thus possibly a basis for the development of
antiglaucomatous drugs. Preclinical in vitro as well as in vivo animal studies are
indispensable before any tests on humans are possible. Rabbit and rat eyes are
both well proven models for the human eye in many biological respects,
although these animal eyes are designed for long-sighted use in the dark and
have limited near vision (Meyer at al. 1972; Artal et al. 1998).
Experimental animals
Like many laboratory animals, rabbits are albinos with non-pigmented eye
structures, which property may have an effect on drug responses. In the rabbit
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eye the trabecular endothelial layer transports aqueous humor direct to the
trabecular meshwork, rendering the uveoscleral outflow a less significant
pathway (Bergmanson 1985). Rabbits are overall ideal for ophthalmological
studies, in that they are easy to handle and have large eyes
easy to manipulate. The rat eye differs anatomically more from the human eye
in having a larger lens and a minor ciliary system, but rats are also largely used
experimental animals. The porcine eye is phylogenetically close to the human
eye after simians (Prince et al. 1960; McMenamin and Steptoe 1991) and many
previous studies have shown that the domestic pig is a suitable subject for a
variety of ophthalmological studies (Wagner et al. 2004; Ruiz-Ederra et al.
2005). Porcine eyes are cheap and easily available from an abattoir. The
average anterior chamber volume of the porcine eye is 300 µl and globe size
almost equal to the human. In addition, the pig eye contains a shallow scleral
sulcus with a wedge-shaped mass of corneoscleral tissue comparable in size to
the human trabecular meshwork (McMenamin and Steptoe 1991). Furthermore,
ultrastructural investigations indicate that the cribriform and subendothelial
regions of the porcine trabecular meshwork have an architecture similar to that
of the primates (Bachmann et al. 2006).
Pressure measurements
Experimental animals used in the present study have a circadian rhythm both in
IOP and BP in relation to their awake/sleep cycle. BP altrerations are more
investigated in rats (Janssen et al. 1992; Lemmer 2006) but also in rabbits (van
den Buuse and Malpas 1997).  The circadian rhythm of normal IOP with peaks
occurs in the evening in nocturnal animals (Moore et al. 1996; Sugimoto et al.
2006) and early in the morning in humans (Liu et al. 1998; Liu et al. 1999), i.e.
the IOP diurnal rhythms of most laboratory animals are approximately 180º out
of phase with these rhythms in humans. To minimize the effect of diurnal
variation in IOP and BP on the results, measurements were made at the same
time of day in all animal experiments. Furthermore, BP as well as IOP may be
influenced by environmental factors or acute stress. To minimize such sources
of error, the animals were pretrained before the beginning of the experiments
and measurements were made by the same person.
The IOP values obtained in this study are in good agreement with earlier
reports, where the same kind of equipment has been used (Kontiola et al. 2001;
Goldblum et al. 2002; Kotikoski et al. 2002; Wang et al. 2005b). The normal IOP
of the awake rabbit is about 20 mmHg (Seidehamel and Dungan 1974; Gregory
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1990), but it varies by even 10 mmHg being highest in the dark hours when the
animal is normally awake (Rowland et al. 1981). The IOP of the conscious rat is
about 18 mmHg (measured by TonoLab) (Wang et al. 2005) showing fluctuation
between mean peak and mean trough 8 mmHg (measured by TonoPen 1)
(Krishna et al. 1995). In the present series, the effect of general anesthesia on
IOP was investigated in normotensive and hypertensive rats. General
anesthesia reduced IOP markedly both in non-treated and in ARB-treated rats,
in agreement with previous findings (Jia et al 2000; Wang et al. 2005).
The animals used in IOP studies here were ocular normotensive. The optimal
situation to evaluate the IOP-lowering effect of different test compounds would
involve preferably congenitally glaucomatous animals, or those with artificially
high IOP, e.g. in animals with laser-induced or alpha chymotrypsin-induced
glaucoma (Shah et al. 2000; Kalesnykas et al. 2007; Nissirios et al. 2008).
However, the availability of naturally occurring glaucomatous animals is limited
and the mechanism of increased IOP in glaucoma is not understood. According
to the literature, oculohypotensive agents involving RAS seem to be  more
efficient in glaucomatous than in normotensive eyes: topical application of
olmesartan (ARB) has been reported to lower IOP in in vivo studies, the effect
being more prominent in ocular-hypertensive animals (Inoue et al. 2001b; Wang
et al. 2005a). Very preliminary data obtained by our study group also indicate
that in rabbits with congenitally elevated IOP, the oculohypotensive effect of
Ang (1-7) is more pronounced than in normotensive animals (unpublished data,
Vaajanen et al. 2007).
The blood pressure measurement methods used in this study were all of high
quality. Our research group has e.g. long experience with the tail-cuff method
used for blood pressure measurements in awaken animals and administration
of RAS blocking antihypertensive drugs mixed in the feed in these hypertensive
rat strains (Mervaala et al. 2001; Pilvi et al. 2006).
Outflow measurements
Outflow facility was measured by the two-level constant pressure infusion
method (Bárány 1964) in order to test the mechanism whereby Ang (1-7)
reduces IOP: via aqueous humor formation or drainage. This system is accurate
but laborious and needs practised workers. It determines the whole aqueous
humor drainage, including trabecular and uveoscleral outflow at two artificial
pressure levels. A disadvantage of this method is that the two different drainage
systems cannot be distinguised from each other, but on the other hand test
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compounds such as large and rapid degrading angiotensin system molecules /
peptides can be administered direct into the anterior chamber in addition to
other dosing systems.
In vitro measurements
RT-PCR methodology measures the expression of mRNA in tissues (Heid et al.
1996; Bustin and Müller 2005). It does not indicate that real protein, i.e.
receptor, is expressed in the tissue but it is more an indication that “tools” for
receptors exist in the tissues studied. Immunohistochemical studies would have
confirmed this finding of mRNA for Mas receptor, but due to the very novel
finding, no immunohistochemical reagents were available to us. mRNA here
was determined from slices cut from a whole eye-ball at the level of the ciliary
body and at the level of the retina without ciliary tissue. It was thus not possible
to establish more specifically the type of cells in which each receptor was
localized. It may be debated whether this receptor expression is only derived
from the vascular bed around the retina and ciliary tissue or even from behind
the blood ocular barriers.
Autoradiography is a semiquantitative method which measures the 125I-[Sar1-
Ile8] AngII binding in receptors, whereby the receptor densities in different
tissues can be determined (Mendelsohn et al. 1987; Stewen et al. 2003). In the
present study, the sections of the whole eye-ball were cut horizontally and the
densities of AT1 and AT2 receptors were measured as mean pixels/square area
from five sections per eye; three squares from the retina and two from the ciliary
body, i.e. more tissue specifically than in RT-PCR. The results obtained by this
analysis were in agreement with those of RT-PCR.
Fluorometric assay. ACE1 activity in ocular tissue was determined using a
fluorometric assay modified from Friedland and Silverstein (1975); many
concentrations of reagent materials were tested before the final set were
accepted.  In the evaluation of ACE2 activity the manufacture’s instructions in
the widely used kit were utilized. One advantage of all in vitro methods is ease
of repetition. The assay of Friedland and Silverstein has been used in enzyme
activity measurements during the past years, the latter method being a more
novel one. The inhibition of both enzyme activations was tested using several
concentrations of bioactive tripeptides, which are known to reduce blood
pressure mainly by ACE inhibition. Captopril, the first developed and now
clinically used ACE1 inhibitor, served as positive control in these tests.
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6.2 OCULAR EFFECTS OF LOCALLY AND SYSTEMICALLY
ADMINISTERED RAS COMPONENTS
The main finding in this study was an oculohypotensive effect of heptapeptide
Ang (1-7), when administered intravitreally into the normotensive rabbit eye.
The most potent concentration of this peptide was 1 mM in an injection volume
of 50 µl and the effect set in as early as two to three hours after application of
the compound. Using specific receptor antagonists it was shown that only A-779
(a specific Mas antagonist) was able to abolish the IOP-lowering effect of Ang
(1-7). This would indicate for the first time that Ang (1-7) acts  via  its  own
receptor type also in the eye tissue in addition to other effects in different
organs recently studied, e.g. heart, vasculature and brains (Santos et al. 2003;
Iwata et al. 2005).
The oculohypotensive effect of Ang (1-7) at a concentration of 1 mM (in an
injection volume of 50 µl) was the basis for the concentrations for other test
compounds used. The approximate final concentration of Ang (1-7) in  the
vitreous space of rabbit was about 20 µM, but potentially much smaller in the
anterior chamber and ciliary body of the animal; i.e at the point of action.
Endogenous Ang II concentrations in the aqueous humor have been reported to
range from 5 to 16 fmol/mg protein in the rabbit (Ramirez et al. 1996) or 0.5 pM
in normal human subjects (Danser et al.1994). The half-life of test compound is
an important factor, and peptides are known to degrade fast. The half-life of Ang
(1-7) in the vitreous space is not known. According to the literature, Ang (1-7)
degrades after systemic administration within 30 min in the canine lung, which
is known to have very high ACE activity (Chappell et al. 1998). However, the
ACE activity in the vitreous is known to be much lower (Ramirez et al. 1996),
which bespeaks a longer half-life in the eye. On the other hand, the effect of a
compound can last far beyond its half-life.
In outflow studies Ang (1-7) had no effect on outflow, while Ang II administered
intracamerally reduced it dose-dependently. Probably Ang (1-7) reduces IOP
via reduction of aqueous humor formation. According to literature Ang (1-7)
promotes release of prostanoids from endothelial and smooth muscle cells,
release of nitric oxide, vasorelaxation, inhibition of vascular cell growth and
fibrosis and, less frequently, vasoconstriction (Muthalif et al. 1998; Santos et al.
2000). It is also known to stimulate the kallikrein-kinin system, having a
vasodilatatory effect (Brosnihan et al. 1996). Finally, it may be that nitric oxide
has a key role at cell level in IOP reduction. The outflow reducing effect of AngII
was not likely to be due to solely an increase in systemic blood pressure, since
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the first elevated pressure had returned to normal by the time of outflow
registration.There are a few reports on the effects of Ang II on aqueous humor
dynamics (Kaufman and Barany 1981; Inoue et al. 2001b). These findings are
in accord with results obtained from monkey studies (Kaufman and Bárány
1981). Ang II has been reported to have effects on uveoscleral outflow in ocular
normotensive rabbits (Inoue et al. 2001b). In the study in question, Ang II was
administered in perfusion fluid at a concentration of 0.5 µM and it diminished the
uveoscleral outflow. It may be that ocular Ang II has only a minor influence on
aqueous humor outflow in eyes under physiological conditions.
Interestingly olmesartan (an AT1 receptor antagonist) administered intravitreally
into one eye lowered IOP in both, the experimental and the contralateral saline
injected eye. To verify that intravitreal injections per se do not cause any
marked decrease in IOP, saline was injected bilaterally and no significant
change in IOP was observed. In addition, in experiments conducted with AT2
and Mas receptor antagonists alone, no significant change in IOP could be
observed neither in experimental nor in the control eyes. The mechanism of IOP
reduction of olmesartan is potentially AT1 receptor blockade, but the reason for
the lowering of pressure in the fellow eye remained obscure.
Topical administration of angiotensins did not influence IOP in rabbits.
Angiotensins are peptides easily degraded to inactive forms and as large
molecules do not readily penetrate through the cornea (Ghate and Edelhauser
2008).
Oral administration of Ang II receptor type 1 blockers (ARBs), olmesartan
medoximil and valsartan, only tended to lower normal IOP in hypertensive rats,
while they reduced blood pressure in SHR and dTGR and even in normotensive
animals. According to autoradiography analysis ARB medication blocked AT1
receptors especially in the retina but also in the ciliaris, the latter being involved
in the regulation of IOP. Here again, presumably intraocular RAS is more
markedly activated in pathological conditions such as glaucoma, when ARBs
may also have a significant lowering effect on IOP. In human studies, orally
administered losartan and captopril have lowered IOP both in normotensive and
glaucomatous subjects, although blood pressure was lowered only in arterial
hypertensive patients (Costagliola et al. 1995; Costagliola et al. 2000).
In Study IV the relationship between the development of hypertension and IOP
was evaluated in arterial hypertensive rats and their controls with/without oral
antihypertensive treatment. The slight but statistically significant relationship
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between IOP and the development of high BP in SHR was apparent in repeated
measurements during eight weeks’ follow-up. On the other hand, double
transgenic RAS "overexpressed" rats showed no relationship between blood
pressure and IOP, which initially high, fell drastically in both non-treated and
ARB-treated rats.
6.3 OCULAR RAS ENZYME ACTIVITY
ACE1 as well ACE2 activity were found in ocular structures; in the retina, ciliaris
and vitreous body. The activity of ACE1 was manifold compared to that of
ACE2, especially in the ciliary body, which is responsible for the formation of
aqueous humor. On the other hand, the inhibition effected by tripeptides IPP,
VPP and LPP, was achieved in much lower concentrations on ACE1 than
ACE2. This means that the negative effects of ACE1 are blocked by tripeptides
known to also have positive cardiovascular effects (Möller et al. 2008; Erdmann
et al. 2008) at concentrations which do not affect the activity of ACE2. These
tripeptides are composed of only three amino acids, which may offer better
penetration through the cornea if applied topically. ACE inhibitors have
generally been reported to have positive ocular effects.
ACE-inhibitors lower Ang II levels in aqueous humor (Osusky et al. 1994). They
might reduce the production of aqueous humor by reducing blood flow in the
ciliary body (Reitsamer and Kiel 2003). In addition, they promote synthesis of
prostaglandins by preventing the breakdown of bradykinin, which could in turn
lower IOP by increasing the uveoscleral outflow (Nilsson et al. 1989; Lotti et al.
1990). The precise mechanism underlying increased uveoscleral outflow is not
known, but there would appear to be associations with increased biosynthesis
of certain matrix metalloproteinases. This would lead to relaxation of the ciliary
muscle and reduction and compaction of extracellular matrix components within
the ciliary muscle, the iris and the sclera and within the tissues of the
uveoscleral outflow pathway. All these effects might facilitate aqueous humor
outflow and thus lower IOP (Weinreb et al. 2002). By preventing bradykinin
breakdown, ACE-inhibitors activate the nitric oxide pathway and the
vasodilatatory effects of prostanoids, and reduce the formation of the
vasoconstrictive peptide endothelin- 1. Endothelin- 1 has been shown to elicit
contraction e.g. in porcine ophthalmic and ciliary arteries and in the human
ophthalmic artery (Yao et al. 1991; Haefliger et al. 1992).
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6.4 SIGNIFICANCE OF RAS EXPRESSION IN OCULAR TISSUES
Although intraocular RAS has already been identified in many eye tissues, the
precise function and significance of local RAS has not yet been established.
Local RAS may have a significant role in the formation of aqueous humor, but
also in its drainage, or intraocular RAS may be involved in both of these
mechanisms. Many RAS components have been shown to be present in
cultured human NPEC, in cells especially responsible for aqueous humor
formation (Lin et al. 1990; Culliane et al. 2002). Ang II has been reported to
activate a Ca2+ signalling system which increases potassium ion channel activity
and triggers aldosterone production (Capponi et al. 1984). These effects are
accompanied by cell volume loss, indicating that Ang II acts as an operated
secretagogue in the NPEC (Culliane et al. 2002). Ang II has also been found to
cause an increase in cytoplasmic sodium concentration due to activation of
Na+/H+ exchange (Hoy and Delamere 2002). In point of fact, mechanisms
related to sodium handling are common pathogenetic factors in both ciliary and
renal tubular epithelia, which may explain the coexistence of glaucoma and
systemic hypertension (Langman et al. 2005). On the other hand, RAS
expression has also been demonstrated in the trabecular meshwork, which is
involved in aqueous humor outflow. Ang II has been reported to be able to
induce cell proliferation in bovine trabecular meshwork cells and increase the
synthesis of collagen in vitro (Shen et al. 2001). It has also been reported that
Ang II administered intracamerally diminishes uveoscleral outflow (Inoue et al.
2001b), as also showed in the present study. Synthetic and natural Ang II have
been reported to reduce IOP in in vivo studies with anesthetized cats when
administered intravenously. The same IOP-lowering effect was seen in the
enucleated, arterially perfused cat and human eye. The mechanism behind the
effect was considered to consist in vasoconstriction of the iris artery (Macri
1965).
There has also been debate as to the origin of RAS; does intraocular
angiotensin originate from local production or from the blood compartment
(Danser et al. 1994). It has been shown that neither Ang  I,  Ang  II nor
angiotensinogen are able to pass the blood-brain barrier (Schelling et al. 1980;
Danser et al. 1994), and the barriers between the eye and circulating blood are
comparable to this (Cuncha-Vaz 1979). If the barrier is intact, circulating
angiotensin cannot reach the vitreous fluid (Danser et al. 1994), whereas if the
barrier is disrupted this becomes possible (Danser et al. 1989). It is therefore
obvious that the levels of angiotensins and other RAS molecules in the eye are
too high to have originated from blood-borne peptides. In porcine ocular tissues
Ang I and II levels have proved to be 5-to 100-fold higher than could be
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accounted for by admixture with blood or diffusion from blood (Danser et al.
1994). Also ACE activity has been shown to be lower in plasma than in ocular
tissues in the rabbit and pig (Ramirez et al. 1996; Geng et al. 2003).
6.5 INTRAOCULAR RAS AND DRUG DEVELOPMENT IN THE
FUTURE
Evidence is now accumulating to indicate that antihypertensive drugs acting on
RAS can also reduce intraocular pressure, and compounds blocking RAS may
eventually prove to be potential antiglaucomatous drugs. Especially agents
increasing ACE2 activity and the formation of Ang (1-7) or activating Mas
receptors are new options, in addition to the classical ACE inhibitors and Ang II
receptor type 1 blockers. An alternative Ang II-generating enzyme, chymase,
may also importantly influence the regulation of IOP. Intraocular chymase
injection has resulted in an increase in IOP in rabbits, which effect was
attenuated by a specific chymase inhibitor (Konno et al. 2005).  Other
interesting and potential agents are renin-inhibitors which can block the whole
renin-angiotensin system by inhibiting the action of renin.
However, the nature of the present experimental compounds constitutes a
significant pharmacokinetic challenge in penetration to the inner parts of the
eye. In addition to their oculohypotensive effect, blockade of ocular RAS may
also exert a neuroprotective effect in glaucoma, and angiotensin-induced
vasoconstriction of ocular blood vessels has been considered a pathogenic
mechanism in optic nerve damage (Mabuchi et al. 2004). Drug intervention may
also have a positive effect on certain ocular diseases like sarcoidosis, in which
intraocular RAS is known to be activated (Immonen et al. 1986). Compounds
acting on RAS may also have a potential in the treatment (Zhang et al. 2007;
Zheng et al. 2007) and prevention of diabetic retinopathy, a leading cause
(Sjølie and Chaturvedi 2002) of blindness in people of working age.
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7 SUMMARY AND CONCLUSIONS
The present study investigated the effects of different exogenous RAS
compounds on IOP and aqueous humor outflow dynamics as well as the
relationship between IOP and development of high BP in in vivo experiments.
The RAS expression in the different eye structures was determined by in vitro
methods using enucleated eyes of experimental animals and fresh enucleated
eyes of domestic pigs.
The main findings are as follows:
1. A degrading product of angiotensins, heptapeptide Ang (1-7), was found
to be the most potent oculohypotensive agent when administered
intravitreally into animals with normal IOP. Topical application of different
RAS compounds did not affect IOP. Systemically administered
antihypertensive agents lowered blood pressure but did not have any
significant lowering effect on normal IOP.
2. A novel angiotensin system receptor type, the Mas receptor for Ang (1-7),
was described for the first time in the eye tissues. An active ACE2, an
enzyme degrading angiotensins to vasorelaxing forms, was also found for
the first time in the ciliary body and vitreous. These findings strongly
indicate the existence of local active intraocular RAS.
3. Ang II given intravitreally decreased dose-dependently aqueous humor
outflow facility while Ang (1-7) had no effect on it suggesting that Ang (1-
7) reduces IOP via inhibition of formation of aqueous humor.
4. There was a significant relationship between development of high blood
pressure and intraocular pressure in spontaneously hypertensive rats
(SHR), but this relationship was not seen in double transgenic rats (dTGR)
with very high basal IOP lowering fast to the level of IOP of SHR.
In conclusion, the function and expression of intraocular RAS in the
normotensive eyes has been in focus in this study. Intraocular RAS seems to be
involved in the regulation of IOP, but probably the local RAS is even more
activated under pathological conditions like in glaucoma. Present findings
suggest the potentials of agents which increase ACE2 activity and formation of
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angiotensin (1-7) or activate Mas receptors as antiglaucomatous drugs in the
future.
ACKNOWLEDGEMENTS
71
8 ACKNOWLEDGEMENTS
The present study was undertaken at the Institute of Biomedicine in the
University of Helsinki and at the Research Center of Santen Oy, Tampere
during the years 2004 to 2009. It was financially supported by the Pävikki and
Sakari Sohlberg Foundation, the Eye Foundation, the Glaucoma Research
Foundation, the Evald and Hilda Nissi Foundation and the Finnish Cultural
Foundation.
First foremost, I wish to express my respectful gratitude to my supervisor
Professor Heikki Vapaatalo, for allowing me to know a great person of
humanity, but most for his encouragement and extremely perspicacious and
prompt advice on pharmacological and scientific problems, always in time.
Without him, I would never have succeeded in this thesis. Second, I thank my
other supervisor, Olli Oksala, Ph.D. for his patience and skilled help in a number
of technical problems of science work and experimental ophthalmology.
I owe my gratitude to Professor of Pharmacology Esa Korpi, Head of the
Institute of Biomedicine, University of Helsinki, for providing possibilities to do
this work as well as Santen Oy, the President Jyrki Liljeroos and especially the
Vice- President of Research and Development, Kari Lehmussaari, and Päivi
Alajuuma, Ph.D.
I am grateful to Hannu Kautiainen, B.A., for his knowledge and advice in the
statistical world in a number of experimental studies to be moulded into
publishable form, to Robert MacGilleon, M.A., for making my ideas and words
understandable in English and Sole Lätti, M.Sc. for her help in illustrations. I
owe my sincerest thanks to the reviewers of this thesis, Professor Ahti
Tarkkanen and Docent Kaj Metsärinne, for their expert comments and
constructive criticism of the manuscript.
My appreciation and thanks are expressed to my co-authors: Docent Ilkka
Tikkanen, Professor Ismo Virtanen and Professor Eero Mervaala, for their
outstanding expertise and unique invaluable provision of new technical
possibilities to study RAS in the eye structures. I thank Päivi Lakkisto, M.D.,
Esko Kankuri, M.D., Ph.D., Jarkko Valjakka, Ph.D. and the especially talented
young researcer, biomedical scientist Satu Luhtala for their contributions to
studies I and II.
ACKNOWLEDGEMENTS
72
I warmly thank all other collaborators, especially Ms Marja Mali and Ms Eeva
Harju and Ms Jaana Tuure, Ms Anneli von Behr, Ms Hanna Wennäkoski, Ms
Anne Reijula, Taru Pilvi, Ph.D., Ms Sari Laakkonen, Riikka Kosonen, M.Sci., Ms
Riina Hatakka and Mr Jarkko Lakkisto for their kind and skilful technical
assistance.
I owe a debt of gratitude to all my close relatives for their positive support and
encouragement during these years of intensive research, especially my mother
Kaija Ikonen for her loving guidance in life, as well as my mother-in-law Arja-
Leena Vaajanen, who both have made this thesis possible by standing behind
me and always taking care of my babies when needed. I am privileged to have
three marvellous children Verna, Iiro and Ilari, who have made my life worth
living. I am proud of my sister Ullakaisa Nieminen and her family, and happy to
have friends like Anna-Maija Antman and Kati Vaajanen. Lastly I want to thank
with loving respect “The Man of my Life”, my dear husband Mika, for being a
long-suffering listener and true friend during these years in addition to being a
strong supporting pillar to our whole family.
Finally I give my profoundest thanks to God, who has given us this wonderful
but complicated world to live in.
Tampere, January 2009
REFERENCES
73
REFERENCES:
Al-Merani SA, Brooks DP, Chapman BJ, Munday KA. The half-lives of angiotensin II,
angiotensin II-amide, angiotensin III, Sar1-Ala8-angiotensin II and renin in the circulatory
system of the rat. J Physiol 1978;278:471-490.
Ardaillou R. Active fragments of angiotensin II: enzymatic pathways of synthesis and biological
effects. Curr Opin Nephrol Hypertens 1997;6:28-34.
Artal P, Herreros de Tejada P, Muñoz Tedó C, Green DG. Retinal image quality in the rodent
eye. Vis Neurosci 1998;15:597-605.
Bacani C, Frishman WH. Chymase: a new pharmacologic target in cardiovascular disease.
Cardiol Review 2006;14:187-193.
Bachmann B, Birke M, Kook D, Eichhorn M, Lütjen-Drecoll E. Ultrastructural and biochemical
evaluation of the porcine anterior chamber perfusion model. Invest Ophthalmol Vis Sci
2006;47:2011-2020.
Bader M, Peters J, Baltatu O, Müller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems:
new insights from experimental animal models in hypertension research. J Mol Med
2001;79:76-102.
Bárány EH. A mathematical formulation of intraocular pressure as dependent on secretion,
ultrafiltration, bulk outflow, and osmotic reabsorption of fluid. Invest Ophthalmol 1963;2:584-590.
Bárány EH. Simultaneous measurement  of changing intraocular pressure and outflow facility in
the vervet monkey by constant pressure infusion. Invest Ophthalmol 1964;3:135-143.
Barbelivien A, MacKenzie ET, Dauphin F. Regional cerebral blood flow responses to
neurochemical stimulation of the substantia innominata in the anaesthetized rat. Neurosci Lett
1995;190:81-84.
Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJ, Burcklé CA, Müller DN, Bader M,
Nguyen G, Danser AH. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding
kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human
(pro)renin receptor. J Hypertens 2007;25:2441-2453.
Bathija R, Gupta N, Zangwill L, Weinreb RN. Changing definition of glaucoma. J Glaucoma
1998;7:165-169.
Becker B. The decline in aqueous secretion and outflow facility with age. Am J Ophthal
1958;46:731-736.
Beevers G, Lip GY, O'Brien E. ABC of hypertension: The pathophysiology of hypertension. BMJ
2001;322:912-916.
Belova LA. Angiotensin II-generating enzymes. Biochemistry (Mosc) 2000;65:1337-1345.
Beneyto Martin P, Fernández-Vila PC, Pérez TM. Determination of the pseudofacility by
fluorophotometry in the human eye. Int Ophthalmol 1995-1996;19:219-223.
Bergmanson JP. The anatomy of the rabbit aqueous outflow pathway. Acta Ophthalmol
1985;63:493-501.
REFERENCES
74
Berguer R, Hottenstein OD, Palen TE, Stewart JM, Jacobson ED. Bradykinin-induced
mesenteric vasodilation is mediated by B2-subtype receptors and nitric oxide. Am J Physiol
1993;264:492-496.
Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for
primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000;107:1287-
1293.
Braun-Mendez E, Fasciolo E, Leloir JC, Munoz JM. La substancia hipertensora de la sangre del
rinon isguemiado. Rev Soc Argent Biol 1939;104.
Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through
kinins and nitric oxide. Hypertension 1996;27:523-528.
Brubaker RF. The flow of aqueous humor in the human eye. Trans Am Ophthalmol Soc
1982;80:391-474.
Brubaker RF. Flow of aqueous humor in humans [The Friedenwald Lecture]. Invest Ophthalmol
Vis Sci 1991;32:3145-3166.
Brubaker RF. Goldmann's equation and clinical measures of aqueous dynamics. Exp Eye Res
2004;78:633-637.
Brubaker RF, Nagataki S, Townsend DJ, Burns RR, Higgins RG, Wentworth W. The effect of
age on aqueous humor formation in man. Ophthalmology 1981;88:283-288.
Buczko W, Matys T, Kucharewicz I, Chabielska E.  The role of endothelium in antithrombotic
effect of the renin-angiotensin system blockade. J Physiol Pharmacol 1999;50:499-507.
Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-912.
Bustin SA, Müller R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in
clinical diagnosis. Clin Sci (Lond) 2005;109:365-379.
Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for
glaucoma therapy. Ophthalmology 1996;103:1916-1924.
Capponi AM, Lew PD, Jornot L, Vallotton MB. Correlation between cytosolic free Ca2+ and
aldosterone production in bovine adrenal glomerulosa cells. J Biol Chem 1984;259:8863-8869.
Caprioli J. The ciliary epithelia and aqueous humor. In: Adler`s Physiology of the Eye, Ed. Hart
WMJ. 9th ed., Mosby-Year Book Inc, St. Louis 1992:228-247.
Carlson KH, McLaren JW, Topper JE, Brubaker RF. Effect of body position on intraocular
pressure and aqueous flow. Invest Ophthalmol Vis Sci 1987;28:1346-1352.
Carretero OA, Oparil S. Essential hypertension. Part I: Definition and etiology. Circulation
2000a;101:329-335.
Carretero OA, Oparil S. Essential hypertension: Part II: Treatment. Circulation 2000b;101:446-
453.
Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-(1-7) by angiotensin-
converting enzyme. Hypertension 1998;31:362-367.
Coca-Prados M, Escribano J. New perspectives in aqueous humor secretion and in glaucoma:
the ciliary body as a multifunctional neuroendocrine gland. Prog Retin Eye Res 2007;26:239-
262.
REFERENCES
75
Costagliola C, Di Benedetto R, De Caprio L, Verde R, Mastropasqua L. Effect of oral captopril
(SQ 14225) on intraocular pressure in man. Eur J Ophthalmol 1995;5:19-25.
Costagliola C, Verolino M, de Rosa ML, Iaccarino G, Ciancaglini M, Mastropasqua L. Effect of
oral losartan potassium on intraocular pressure in normotensive and glaucomatous human
subjects. Exp Eye Res 2000;71:167-171.
Crosson CE: Adenosine receptor activation modulates intraocular pressure in rabbits. J
Pharmacol Exp Ther 1995;273:320-326.
Crowley SD, Gurley SB, Coffman TM. AT(1) receptors and control of blood pressure: the kidney
and more...Trends Cardiovasc Med 2007;17:30-34.
Culliane AB, Leung PS, Ortgo J, Coca-Prados M, Harvey BJ. Renin-angiotensin system
expression and secretory function in cultured human ciliary body non-pigmented epithelium. Br
J Ophthalmol 2002;86:676-683.
Cunha-Vaz J. The blood-ocular barriers. Surv Ophthalmol 1979;23:279-296.
Cunha-Vaz JG. The blood-retinal barrier system. Basic concepts and clinical evaluation. Exp
Eye Res 2004;78:715-721.
Danser AH, van den Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E, de Jong PT,
Schalekamp MA. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and
without diabetic retinopathy. J Clin Endocrinol Metab 1989; 68:160-167.
Danser AHJ, Derkx FHM, Admiraal PJJ, Deinum J, de Jong PTVM, Schalekamp MADH.
Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994;35:1008-1018.
De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology
XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-472.
Derkx FH, Alberda AT, Zeilmaker GH, Schalekamp MA. High concentrations of immunoreactive
renin, prorenin and enzymatically-active renin in human ovarian follicular fluid. Br J Obstet
Gynaecol 1987;94:4-9.
Deschepper CF, Mellon SH, Cumin F, Baxter JD, Ganong WF. Analysis by
immunocytochemistry and in situ hybridization of renin and its mRNA in kidney, testis, adrenal,
and pituitary of the rat. Proc Natl Acad Sci USA 1986;83:7552-7556.
Deva NC, Insull E, Gamble G, Danesh-Meyer HV. Risk factors for first presentation of glaucoma
with significant visual field loss. Clin Experiment Ophthalmol 2008;36:217-221.
Dielemans I, Vingerling JR, Algra D, Hofman A, Grobbee DE, de Jong PT. Primary open-angle
glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population.
The Rotterdam Study. Ophthalmology 1994;102:54-60.
Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B,
Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-
related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87:1-
9.
Erdmann K, Cheung BW, Schröder H. The possible roles of food-derived bioactive peptides in
reducing the risk of cardiovascular disease.J Nutr Biochem 2008;19:643-654.
Ericson LA. Twenty-four hourly variations in the inflow of the the aqueous humor. Acta
Ophthalmol (Copenh) 1958;36: 381-385.
REFERENCES
76
Ewert S, Laesser M, Johansson B, Holm M, Aneman A, Fandriks L. The angiotensin II receptor
type 2 agonist CGP 42112A stimulates NO production in the porcine jejunal mucosa. BMC
Pharmacol 2003;3:2.
Ferrario CM, Chappell MC. Novel angiotensin peptides. Cell Mol Life Sci 2004;61:2720-2727.
Ferrario CM, Santos RA, Brosnihan KB, Block CH, Schiavone MT, Khosla MC, Greene LJ. A
hypothesis regarding the function of angiotensin peptides in the brain. Clin Exp Hypertens A
1988;10:107-121.
Ferreira AJ, Raizada MK. Are we poised to target ACE2 for the next generation of
antihypertensives? J Mol Med 2008;86:685-690.
Ferreira SH. A bradykinin-potentiating factor (BPF) present in the venom of Bothorps jararaca.
Br J P 1965;24:163-169.
Ford WR, Clanachan AS, Jugdutt BI. Opposite effects of angiotensin AT1 and AT2 receptor
antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working
rat hearts. Circulation 1996;94:3087-3089.
Friedland, J., Silverstein, E. A sensitive fluorimetric assay for serum angiotensin-converting
enzyme. Am J Clin Pathol 1975;66:416-424.
Fyhrquist F, Metsärinne K, Tikkanen I. Role of angiotensin II in blood pressure regulation and in
the pathophysiology of cardiovascular disorders. J Hum Hypertens 1995;5:19-24.
Ganten D, Schelling P, Vecsei P, Ganten U. Iso-renin of extrarenal origin. "The tissue
angiotensinogenase systems".Am J Med 1976;31:760-772.
Geng L, Persson K, Nilsson SFE. Angiotensin converting enzyme (ACE) activity in porcine
ocular tissue: effects of diet and ACE inhibitors. J Pharm Ther 2003;19:589-596.
Ghate D, Edelhauser HF. Barriers to glaucoma drug delivery. J Glaucoma 2008;17:147-156.
Gherghel D, Hosking SL, Orgül S. Autonomic nervous system, circadian rhythms, and primary
open-angle glaucoma. Surv Ophthalmol 2004;49:491-508.
Giardina WJ, Kleinert HD, Ebert DM, Wismer CT, Chekal MA, Stein HH. Intraocular pressure
lowering effects of the renin inhibitor ABBOTT-64662 diacetate in animals. J Ocul Pharmacol
1990;6:75-83.
Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome
Res 1996;6:995-1001.
Goldblum D, Kontiola AI, Mittag T, Chen B, Danias J. Non-invasive determination of intraocular
pressure in the rat eye. Comparison of an electronic tonometer (TonoPen), and a rebound
(impact probe) tonometer. Graefe`s Arch Clin Exp Ophthalmol 2002;240:942-946.
Goldmann H. Abflussdruck, Minutenvolumen und Widerstand der Kammerwasser-Strömung
des Menschen. Doc Ophthalmol 1951;5-6:278-356.
Goldstein DA, Tessle HH. Classification, symptoms and signs of uveitis. In: Duane`s
Ophthalmology, Eds. Tasman W, Jaeger EA. CD-ROM edition, Lippincot Williams et Wilkins
2006; Vol 4, Ch 32.
Green K, Sherman SH, Laties AM, Pederson JE, Gaasterland DE, MacLellan HM. Fate of
anterior chamber tracers in the living rhesus monkey eye with evidence for uveo-vortex outflow.
Trans Ophthalmol Soc U K 1977; 97:731-739.
REFERENCES
77
Gregory DS. Timolol reduces IOP in normal NZW rabbits during the dark only. Invest
Ophthalmol Vis Sci 1990;31:715-721.
Grieshaber MC, Flammer J. Blood flow in glaucoma. Curr Opin Ophthalmol 2005;16:79-83.
Grisé C, Boucher R, Thibault G, Genest J. Formation of angiotensin II by tonin from partially
purified human angiotensinogen. Can J Biochem 1981;59:250-255.
Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK,
Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am
J Physiol Heart Circ Physiol 2007;292:736-742.
Gross F, Lichtlen P. Pressor substances in kidneys of renal hypertensive rats with and without
adrenals. Proc Soc Exp Biol Med 1958a;98:341-345.
Gross F, Lichtlen P. Experimental renal hypertension: renin content of kidneys in intact and
adrenalectomized rats given cortexone. Am J Physiol 1958b;195:543-548.
Gross F, Schmidt H. Aldosterone overdosage in the rabbit. Acta Endocrinol (Copenh)
1958;28:467-478.
Grosskreutz C, Netland PA. Low-tension glaucoma. Int Ophthalmol Clin 1994;34:173-185.
Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology, and molecular biology of
renin secretion. Physiol Rev 1990;70:1067-1116.
Haefliger IO, Flammer J, L?scher TF. Nitric oxide and endothelin-1 are important regulators of
human ophthalmic artery. Invest Ophthalmol Vis Sci 1992;33:2340-2343.
Hall JE. Historical perspective of the renin-angiotensin system. Mol Biotechnol 2003;24:27-39.
Hamada T, Murata T, Narita K, Takahashi T, Wada Y, Kimura H, Yoshida H. The clinical
significance of abnormal diurnal blood pressure variation in healthy late middle-aged and older
adults. Blood Press 2008;10:1-7.
Hammond BR, Bhattacherjee P. Calibration of the Alcon applanation pneumatonograf and
Perkins tonometer for use in rabbits and cats. Curr Eye Res 1984;3:1155-1158.
Handa RK. Metabolism alters the selectivity of angiotensin-(1-7) receptor ligands for angiotensin
receptors. J Am Soc Nephrol 2000;11:1377-1386.
Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res
1996;6:986-994.
Hemmelgarn BR, McAlister FA, Grover S, Myers MG, McKay DW, Bolli P, Abbott C, Schiffrin
EL, Honos G, Burgess E, Mann K, Wilson T, Penner B, Tremblay G, Milot A, Chockalingam A,
Touyz RM, Tobe SW; Canadian Hypertension Education Program. The 2006 Canadian
Hypertension Education Program recommendations for the management of hypertension: Part
I--Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2006;22:573-
581.
Hirsch AT, Pinto YM, Schunkert H, Dzau VJ. Potential role of the tissue renin-angiotensin
system in the pathophysiology of congestive heart failure. Am J Cardiol 1990;66:22-32.
Hong F, Ming L, Yi S, Zhanxia L, Yongquan W, Chi L. The antihypertensive effect of peptides: a
novel alternative to drugs? Peptides 2008;29:1062-1071.
Hoy Y, Delamere NA. Influence of ANG II on cytoplasmic sodium in cultured rabbit
nonpigmented ciliary epithelium. Am J Physiol Cell Physiol 2002;283:552-559.
REFERENCES
78
Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy:
implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular
disease. J Am Soc Nephrol 2003;14:1738-1747.
Immonen I, Friberg K, Grönhagen-Riska C, von Willebrand E, Fyhrquist F. Angiotensin-
converting enzyme in sarcoid and chalazion granulomas of the conjunctiva. Acta Ophthalmol
(Copenh) 1986;64:519-521.
Immonen I, Friberg K, Sorsila R, Fyhrquist F. Concentration of angiotensin-converting enzyme
in tears of patients with sarcoidosis. Acta Ophthalmol (Copenh) 1987;65:27-29.
Infeld DA, O'Shea JG. Glaucoma: diagnosis and management. Postgrad Med J 1998;74:709-
715.
Inoue T, Yokoyoma T, Mori Y, Sasaki Y, Hosokawa T, Yanagisawa H, Koike H. The effect of
topical CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure and aqueous
humor dynamics in rabbits. Curr Eye Res 2001a;23:133-138.
Inoue T, Yokoyoma T, Koike H. The effect of angiotensin II on uveoscleral outflow in rabbits.
Curr Eye Res 2001b;23:139-143.
Iusuf D, Henning RH, van Gilst WH, Roks AJ. Angiotensin-(1-7): Pharmacological properties
and pharmacotherapeutic perspectives. Eur J Pharmacol 2008;13: 303-312.
Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH. Angiotensin (1-
7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects.
Am J Physiol Heart Circ Physiol 2005;289:2356-2363.
Jackson KE. Renin and Angiotensin. In: Goodman & Gilman`s The pharmacological basis of
therapeutics, Eds. Hardman JG, Limbird LE.  11th ed., Medical Publishing Division, New York
2006:789-814.
Jaiswal N, Diz DI, Chappell MC, Khosla MC, Ferrario CM. Stimulation of endothelial cell
prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension
1992;19:49-55.
Jampel HD. Target pressure in glaucoma therapy. J Glaucoma 1997;6:133-138.
Janssen BJA, Tyssen CM, Struijker Boudier HAJ, Hutchins PM. 24-h homeodynamic states of
arterial blood pressure and pulse interval in conscious rats. J Appl Physiol 1992;73:754-761.
Jauhiainen T, Collin M, Narva M, Poussa T, Cheng JZ, Vapaatalo H, Korpela R. Effect of long-
term intake of milk peptides and minerals on blood pressure and arterial function in
spontaneously hypertensive rats. Milk Sci Int 2005a;60:358-363.
Jauhiainen T, Vapaatalo H, Poussa T, Kyrönpalo S, Rasmussen M, Korpela R. Lactobacillus
helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory
blood pressure measurement. Am J Hypertens 2005b;18:1600-1605.
Jauhiainen T, Korpela R. Milk peptides and blood pressure. J Nutr 2007;137:825-829.
Jia L, Cepurna WO, Johnson EC, Morrison JC. Effect of general anesthetics on IOP in rats with
experimental aqueous outflow obstruction. Invest Ophthalmol Vis Sci 2000;41:3415-3419.
Jin D, Takai S, Yamada M, Sakaguchi M, Miyazaki M. Beneficial effects of cardiac chymase
inhibition during the acute phase of myocardial infarction. Life Sci 2002;71:437-446.
Johnson M. 'What controls aqueous humour outflow resistance?'. Exp Eye Res 2006;82: 545-
557.
REFERENCES
79
Kainulainen K, Perola M, Terwilliger J, Kaprio J, Koskenvuo M, Syvänen AC, Vartiainen E,
Peltonen L, Kontula K. Evidence for involvement of the type 1 angiotensin II receptor locus in
essential hypertension. Hypertension 1999;33:844-849.
Kakar SS, Sellers JC, Devor DC, Musgrove LC, Neill JD. Angiotensin II type-1 receptor subtype
cDNAs: differential tissue expression and hormonal regulation. Biochem Biophys Res Commun
1992;183:1090-1096.
Kalesnykas G, Niittykoski M, Rantala J, Miettinen R, Salminen A, Kaarniranta K, Uusitalo H. The
expression of heat shock protein 27 in retinal ganglion and glial cells in a rat glaucoma model.
Neuroscience 2007;150:692-704.
Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T. Molecular
cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase
inhibition. J Biol Chem 1993;268:24543-24546.
Kaufman PL, Bárány EH. Loss of acute pilocarpine effect on outflow facility following surgical
disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the cynomolgus
monkey. Invest Ophthalmol 1976;15:793-807.
Kaufman PL, Bárány EH. Adrenergic drug effects on aqueous outflow facility following ciliary
muscle retrodisplacement in the cynomolgus monkey. Invest Ophthalmol Vis Sci 1981;20:644-
651.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of
hypertension: analysis of worldwide data. Lancet 2005;365:217-223.
Khaw PT, Shah P, Elkington AR. Glaucoma--2: treatment. BMJ 2004;17;156-158.
Klein BE, Klein R, Knudtson MD. Intraocular pressure and systemic blood pressure: longitudinal
perspective: The Beaver Dam Eye Study. Br J Ophthalmol 2005;89:284-287.
Klickstein LB, Kaempfer CE, Wintroub BU. The granulocyte-angiotensin system. Angiotensin I-
converting activity of cathepsin G. J Biol Chem 1982;257:15042-15046.
Kokkonen JO, Saarinen J, Kovanen PT. Angiotensin II formation in the human heart: an ACE or
non-ACE mediated pathway? Ann Med 1998;30:9-13.
Konno T, Maruichi M, Takai S, Oku H, Sugiyama T, Uchibori T, Nagai A, Kogi K, Ikeda T,
Miyazaki M. Effect of chymase on intraocular pressure in rabbits. Eur J Pharmacol
2005;524:132-137.
Kontiola AI, Goldblum D, Mittag T, Danias J. The induction/impact tonometer: a new instrument
to measure intraocular pressure in the rat. Exp Eye Res 2001;73:781-785.
Kööbi P, Kalliovalkama J, Jolma P, Rysä J, Ruskoaho H, Vuolteenaho O, Kähönen M, Tikkanen
I, Fan M, Ylitalo P, Pörsti I. AT1 receptor blockade improves vasorelaxation in experimental
renal failure. Hypertension 2003;41:1364-1371.
Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM,
Gembardt F, Kellett E, Martini L, Vanderheyden P, Schultheiss HP, Walther T. G-protein-
coupled receptor Mas is a physiological antagonist of the angiotensin II type I receptor.
Circulation 2005;111:806-813.
Kotikoski H, Alajuuma P, Moilanen E, Salmenperä P, Oksala O, Laippala P, Vapaatalo H.
Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP.
J Ocul Pharmacol Ther 2002;18:11-23.
REFERENCES
80
Kramkowski K, Mogielnicki A, Buczko W. The physiological significance of the alternative
pathways of angiotensin II production. J Physiol Pharmacol 2006;57:529-539.
Krishna R, Mermoud A, Baerveldt G, Minckler DS. Circadian rhythm of intraocular pressure: a
rat model. Ophthalmic Res 1995;27:163-167.
Krootila K, Palkama A, Uusitalo H: Effect of serotonin and its antagonist (ketanserin) on
intraocular pressure in the rabbit. J Ocul Pharmacol. 1987;3:279-290.
Kucharewicz I, Pawlak R, Matys T, Chabielska E, Buczko W. Angiotensin-(1-7): an active
member of the renin-angiotensin system. J Physiol Pharmacol 2002;53:533-540.
Kwon YH, Caprioli J. Primary open angle glaucoma. In: Duane`s Ophthalmology, Eds Tasman
W, Jaeger EA.  CD-ROM edition. Lippincot Williams et Wilkins 2006;Vol 3, Ch 45.
Lakkisto P, Palojoki E, Bäcklund T, Saraste A, Tikkanen I, Voipio-Pulkki LM, Pulkki K.
Expression of heme oxygenase-1 in response to myocardial infarction in rats. J Mol Cell Cardiol
2002;34:1357-1365.
Langman MJS, Lancashire RJ, Cheng KK, Stewart PM. Systemic hypertension and glaucoma:
mechanisms in common and co-occurrence. Br J Ophthalmol 2005;89:960-963.
Laragh JH, Ulick S, Januszewich V, Deming QB, Kelly WG, Lieberman S. Aldosterone secretion
and primary and malignant hypertension. J Clin Invest 1960;39:1091-1106.
Larsson LI, Pach JM, Brubaker RF. Aqueous humor dynamics in patients with diabetes mellitus.
Am J Ophthalmol 1995;120:362-367.
Lemmer B. Importance of circadian rhythms for regulation of the cardiovascular system-studies
in animal and man. Conf Proc IEEE Eng Med Biol Soc 2006;1:168-170.
Lemos VS, Silva DM, Walther T, Alenina N, Bader M, Santos RA. The endothelium-dependent
vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-
knockout mice. J Cardiovasc Pharmacol 2005;46:274-279.
Leske MC, Connell AM, Wu SY, Hyman LG, Schachat AP. Risk factors for open angle
glaucoma. The Barbados Eye Study. Arch Ophthalmol 1995;113:918-924.
Lin C, Stone RA, Wax MB. Angiotensin binding sites in rabbit anterior uvea and human ciliary
epithelial cells. Invest Ophthalmol Vis Sci 1990;31:147-152.
Liu JH, Kripke DF, Hoffman RE, Twa MD, Loving RT, Rex KM, Gupta N, Weinreb RN. Nocturnal
elevation of IOP in young adults. Invest Ophthalmol Vis Sci 1998;39:2707-2712.
Liu JH, Kripke DF, Twa MD, Hoffman RE, Mansberger SL, Rex KM, Girkin CA, Weinreb RN.
Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis
Sci 1999;40:2912-2917.
Lotti VJ, Pawlowski N. Prostaglandins mediate the ocular hypotensive action of the angiotensin
converting enzyme inhibitor MK-422 (enalaprilat) in African green monkeys. J Ocul Pharmacol
1990;6:1-7.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol
reagent. J Biol Chem 1951;193:265-275.
Luft FC. Workshop: mechanisms and cardiovascular damage in hypertension. Hypertension
2001;37:594-598.
REFERENCES
81
Lütjen-Drecoll E, Gabelt BT, Tian B, Kaufman PL. Outflow of aqueous humor. J Glaucoma
2001;10:42-44.
Mabuchi F, Aihara M, Mackey MR, Lindsey JD, Weinreb RN. Regional optic nerve damage in
experimental mouse glaucoma. Invest Ophthalmol Vis Sci 2004;45:4352-4358.
Macri FJ. The action of angiotensin on intraocular pressure. Arch Ophthalmol 1965;73:528-539.
Maruichi M, Oku H, Takai S, Muramatsu M, Sugiyama T, Imamura Y, Minami M, Ueki M, Satoh
B, Sakaguchi M, Miyazaki M, Ikeda T. Measurement of activities in two different angiotensin II
generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of
vitreoretinal diseases: a possible involvement of chymase in the pathogenesis of macular hole
patients. Current Eye Res 2004;29:321-325.
McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ. Current management of
glaucoma and the need for complete therapy. Am J Manag Care 2008;14:20-27.
McMenamin PG, Steptoe RJ. Normal anatomy of the aqueous humour outflow system in the
domestic pig eye. J Anat 1991;178:65-77.
Mendelsohn FA, Millan M, Quirion R, Aguilera G, Chou ST, Catt KJ. Localization of angiotensin
II receptors in rat and monkey kidney by in vitro autoradiography. Kidney Int Suppl 1987;20:40-
44.
Mervaala EM, Cheng ZJ, Tikkanen I, Lapatto R, Nurminen K, Vapaatalo H, Müller DN, Fiebeler
A, Ganten U, Ganten D, Luft FC. Endothelial dysfunction and xanthine oxidoreductase activity in
rats with human renin and angiotensinogen genes. Hypertension 2001;37:414-418.
Mervaala E, Müller DN, Schmidt F, Park JK, Gross V, Bader M, Breu V, Ganten D, Haller H, Luft
FC. Blood pressure-independent effects in rats with human renin and angiotensinogen genes.
Hypertension 2000;35:587-594.
Metsärinne KP, Helin KH, Saijonmaa O, Stewen P, Sirviö ML, Fyhrquist FY. Tissue-specific
regulation of angiotensin-converting enzyme by angiotensin II and losartan in the rat. Blood
Pressure 1996;5:363-370.
Meyer DL, Meyer-Hamme S, Schaefer KP. Electrophysiological investigation of refractive state
and accommodation in the rabbit's eye. Pflüger`s Arch 1972;332:80-86.
Millar JC, True Gabelt B, Kaufman PL. Aqueous humor dynamics. In: Duane`s Ophthalmology,
Eds. Tasman W, Jaeger EA. CD-ROM edition, Lippincot Williams & Wilkins 2006;Vol 3, Ch 45.
Mitchell P, Lee AJ, Rochtcina E, Wang JJ. Open-angle glaucoma and systemic hypertension:
The Blue Mountains Eye Study. J Glaucoma 2004;13:319-326.
Mizoue S, Iwai M, Ide A, Suzuki J, Horiuchi M, Shiraishi A, Ohashi Y. Role of angiotensin II
receptor subtypes in conjunctival wound healing. Curr Eye Res 2006;31:129-136.
Miyazaki M, Takai S. Tissue angiotensin II generating system by angiotensin-converting
enzyme and chymase. J Pharmacol Sci 2006;100:391-397.
Moore CG, Johnson EC, Morrison JC. Circadian rhythm of intraocular pressure in the rat. Curr
Eye Res 1996;15:185-191.
Möller NP, Scholz-Ahrens KE, Roos N, Schrezenmeir J. Bioactive peptides and proteins from
foods: indication for health effects. Eur J Nutr 2008;47:171-182.
Morris BJ. New possibilities of intracellular renin and inactive renin now that the structure of the
human renin gene has been elucidated. Clin Sci 1986;71:345-355.
REFERENCES
82
Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA
encoding the vascular type-1 angiotensin II receptor. Nature 1991;351:233-236.
Mustafa T, Lee JH, Chai SY, Albiston AL, McDowall SG, Mendelsohn FA. Bioactive angiotensin
peptides: focus on angiotensin IV. J Renin Angiotensin Aldosterone Syst 2001;2:205-210.
Muthalif MM, Benter IF, Uddin MR, Harper JL, Malik KU. Signal transduction mechanisms
involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in
rabbit aortic smooth muscle cells. J Pharmacol Exp Ther 1998;284:388-398.
Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of
proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys
Res Commun 2006;350:1026-1031.
Nakajima M, Mukoyama M, Pratt RE, Horiuchi M, Dzau VJ. Cloning of cDNA and analysis of the
gene for mouse angiotensin II type 2 receptor. Biochem Biophys Res Commun 1993;197:393-
399.
Nasjletti A, Masson GMC. Hepatic origin of renin substrate. Can J Physiol Pharmacol
1971;49:1311-1315.
Ng KK, Vane JR. Conversion of angiotensin I to angiotensin II. Nature 1967;216:762-766.
Nguyen G, Danser AJ. Prorenin and (pro)renin receptor: a review of available data from in vitro
studies and experimental models. Exp Physiol 2008;9:119-123.
Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible
mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the
cynomolgus monkey. Exp Eye Res 1989;48:707-716.
Nishimoto M, Takai S, Kim S, Jin D, Yuda A, Sakaguchi M, Yamada M, Sawada Y, Kondo K,
Asada K, Iwao H, Sasaki S, Miyazaki M. Significance of chymase-dependent angiotensin II-
forming pathway in the development of vascular proliferation. Circulation 2001;104:1274-1279.
Nissirios N, Chanis R, Johnson E, Morrison J, Cepurna WO, Jia L, Mittag T, Danias J.
Comparison of anterior segment structures in two rat glaucoma models: an ultrasound
biomicroscopic study. Invest Ophthalmol Vis Sci 2008;49:2478-2482.
Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in
angio-oedema. Lancet 1998;351:1693-1697.
Oishi Y, Ozono R, Yoshizumi M, Akishita M, Horiuchi M, Oshima T. AT2 receptor mediates the
cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. Life
Sci 2006;80:82-88.
Okunishi H, Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin
II-generating enzymes in the aortic wall. Biochem Biophys Res Commun 1987;149:1186-1192.
Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting
enzyme: new class of orally active antihypertensive agents. Science 1977;196:441-444.
Osusky R, Nussberger J, Amstutz C, Flammer J, Brunner HR. Individual measurements of
angiotensin II concentrations in aqueous humor of the eye. Eur J Ophthalmol 1994;4:228-233.
Owen CA, Campbell EJ. Angiotensin II Generation at the cell surface of activated neutrophils:
novel cathepsin G-mediated catalytic activity that is resistant to Inhibition. Immunol
1998;160:1436-1443.
REFERENCES
83
Page IH, Helmer OM. A crystalline pressor substance (angiotonin) resulting from the reaction
between renin and renin activator. J Exp Med 1940;71:29-42.
Paul M, Poyan Mehr A, Kreutz R.  Physiology of local renin-angiotensin systems. Physiol Rev
2006;86:747-803.
Pilvi TK, Jauhiainen T, Cheng ZJ, Mervaala EM, Vapaatalo H, Korpela R. Lupin protein
attenuates the development of hypertension and normalises the vascular function of NaCl-
loaded Goto-Kakizaki rats. J Physiol Pharmacol 2006;57:167-176.
Pinheiro SV, Simões e Silva AC, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED,
Pesquero JB, Walther T, Alenina N, Bader M, Bleich M, Santos RA. Nonpeptide AVE 0991 is an
angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 2004;44:490-496.
Prince JH, Diesem CD, Eglitis I, Ruskell GL. The pig. In: Anatomy and histology of the eye and
orbit of domestic animals, Ed. Thomas CC.  Springfield, Illinois 1960: 210-230.
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br
J Ophthalmol 2006;90:262-267.
Ramirez M, Davidson EA, Luttenauer L, Elena PP, Cumin F, Mathis GA, De Gasparo M. The
renin-angiotensin system in the rabbit eye. J Ocul Pharmacol Ther 1996;12:299-312.
Reiss GR, Lee DA, Topper JE, Brubaker RF. Aqueous humor flow during sleep. Invest
Ophthalmol Vis Sci 1984;25:776-778.
Reitsamer HA, Kiel JW. Relationship between ciliary body blood flow and aqueous production in
rabbits. Invest Ophthalmol Vis Sci 2003;44:3967-3971.
Roks AJ, van Geel PP, Pinto YM, Buikema H, Henning RH, de Zeeuw D, van Gilst WH.
Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension
1999;34:296-301.
Rowland JM, Potter DE, Reiter RJ. Circadian rhythm in intraocular pressure: a rabbit model.
Curr Eye Res 1981;1:169-173.
Ruiz-Ederra, J., Garcia, M., Hernandez, M., Urcola, H., Hernandez-Barbachano, E., Araiz, J.,
Vecino, E. The pig eye as a novel model of glaucoma. Exp Eye Res 2005;81:561-569.
Ruiz-Ortega M, Esteban V, Egido J. The regulation of the inflammatory response through
nuclear factor-kappab pathway by angiotensin IV extends the role of the renin angiotensin
system in cardiovascular diseases. Trends Cardiovasc Med 2007;17:19-25.
Ruiz-Ortega M, Lorenzo O, Rupérez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J.
Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension
2001;38:1382-1387.
Ruskell GL. Innervation of the anterior segment of the eye. In: Basic aspects of Glaucoma
Research, Ed. Lütjen-Drecoll E. Schattauer-Verlag, Stuttgart 1982: 49-57.
Ruskoaho H. Regression of cardiac hypertrophy with drug treatment in spontaneously
hypertensive rats. Med Biol 1984; 62:263-276.
Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin (1-7): an update. Regulatory
Peptides 2000;91:45-62.
Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S,
Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss
REFERENCES
84
HP, Speth R, Walther T. Angiotensin (1-7) is an endogenous ligand for the G-protein-coupled
receptor Mas. Proc Natl Acad Sci USA 2003;8:8258-8263.
Sato A, Sato, Y. Cholinergic neural regulation of regional cerebral blood flow. Alzheimer Dis
Assoc Disord 1995;9:28-38.
Satofuka S, Ichihara A, Nagai N, Yamashiro K, Koto T, Shinoda H, Noda K, Ozawa Y, Inoue M,
Tsubota K, Suzuki F, Oike Y, Ishida S. Suppression of ocular inflammation in endotoxin-induced
uveitis by inhibiting nonproteolytic activation of prorenin. Invest Ophthalmol Vis Sci
2006;47:2686-2692.
Savaskan E, Loffler KU, Meier F, Muller-Spahn F, Flammer J, Meyer P. Immunohistochemical
localization of angiotensin-converting enzyme, angiotensin II and AT1 receptor in human ocular
tissues. Ophthalmic Res 2004;36:312-320.
Schelling P, Ganten U, Sponer G, Unger T, Ganten D. Components of the renin angiotensin
system in cerebrospinal fluid of rats and dogs with special consideration of the origin and fate of
angiotensin II. Neuroendocrinology 1980;31:297-308.
Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and
cardiovascular risk. Lancet. 2007;7:1208-1219.
Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood
pressure and sodium and potassium homeostasis. In: Hypertension: Pathophysiology,
diagnosis and management, Eds. Laragh JN, Brenner BM. Raven Press, New York 1990:1287-
1311.
Sealey JE, White RP, Laragh JH, Case DB, Rubin AL. Studies of plasma aldosterone in
anephric people: evidence for the fundamental role of the renin system in maintaining
aldosterone secretion. J Clin Endocrinol Metab 1978 ;47:52-60.
Seidehamel RJ, Dungan KW. Characteristics and pharmacologic utility of an intraocular
pressure (IOP) model in unanesthetized rabbits. Invest Ophthalmol 1974;13:319-322.
Semple PF, Boyd AS, Dawes PM, Morton JJ. Angiotensin II and its heptapeptide (2-8),
hexapeptide (3-8), and pentapeptide (4-8) metabolites in arterial and venous blood of man. Circ
Res 1976a;39:671-678.
Semple PF, Brown JJ, Lever AF, MacGregor J, Morton JJ, Powell-Jackson JD, Robertson JI.
Renin, angiotensin II and III in acute renal failure: note on the measurement of angiotensin II
and III in rat blood. Kidney Int Suppl 1976b;6:169-176.
Senanayake P, Drazba J, Shadrach K, Milsted A, Rungger-Brandle E, Nishiyama K, Miura S,
Karnik S, Sears JE, Hollyfield JG. Angiotensin II and its receptor subtypes in the human retina.
Invest Ophthalmol Vis Sci 2007;48:3301-3311.
Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release
after angiotensin receptor stimulation. Hypertension 1995;26:164-170.
Shah GB, Sharma S, Mehta AA, Goyal RK. Oculohypotensive effect of angiotensin-converting
enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol
2000;36:169-175.
Shen F, Zhang L, Liu T. Effects of angiotensin II on the 3H-TdR incorporation and synthesis of
collagen in cultured bovine trabecular meshwork cells (Article in Chinese), Yan Ke Xue Bao
2001;17:209-212.
REFERENCES
85
Sherman DD, Burkat CN, Lemke BN. Orbital anatomy and its clinical applications. In: Duane`s
Ophthalmology, Eds. Tasman W, Jaeger EA. CD-ROM edition. Lippincot Williams et Wilkins
2006; Vol 2, Ch 21.
Shiota N, Saegusa Y, Nishimura K, Miyazaki M. Angiotensin II-generating system in dog and
monkey ocular tissues. Clin Exp Pharmacol Ther 1997;24:243-248.
Siegel MJ, Lee PY, Podos SM, Mittag TW. Effect of topical pergolide on aqueous dynamics in
normal and glaucomatous monkeys. Exp Eye Res 1987;44:227-233.
Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RA, Lemos VS. Evidence for
a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides
2007;28:702-707.
Sjølie AK, Chaturvedi N. The retinal renin-angiotensin system: implications for therapy in
diabetic retinopathy. J Hum Hypertens 2002;16:42-46.
Skeggs LT, Kahn JR, Shumway NP. The preparation and function of the hypertension
converting enzyme. J Exp Med 1956;103:295-299.
Sommer A. Glaucoma risk factors observed in the Baltimore Eye Survey. Curr Opin Ophthalmol
1996;7:93-98.
Sramek SJ, Wallow IH, Day RP, Ehrlich EN. Ocular renin-angiotensin: immunohistochemical
evidence for the presence of prorenin in eye tissue. Invest Ophthalmol Vis Sci 1988;29:1749-
1752.
Sramek SJ, Wallow IHL, Tewksbury DA, Brandt CR, Poulsen GL. An ocular renin-angiotensin
system. Immunohistochemistry of angiotensinogen. Invest Ophthalmol Vis Sci 1992;33:1627-
1632.
Stern N, Sowers JR, McGinty D, Beahm E, Littner M, Catania R, Eggena P. Circadian rhythm of
plasma renin activity in older normal and essential hypertensive men: relation with inactive
renin, aldosterone, cortisol and REM sleep. Hypertension 1986;4:543-550.
Stewen P, Mervaala E, Karppanen H, Nyman T, Saijonmaa O, Tikkanen I, Fyhrquist F. Sodium
load increases renal angiotensin type 1 receptors and decreases bradykinin type 2 receptors.
Hypertens Res 2003;26:583-589.
Su JB. Kinins and cardiovascular diseases. Curr Pharm Des 2006;12:3423-3435.
Sugimoto E, Aihara M, Ota T, Araie M. Effect of light cycle on 24-hour pattern of mouse
intraocular pressure. J Glaucoma 2006;15:505-511.
Sung CP, Arleth AJ, Storer BL, Ohlstein EH. Angiotensin type 1 receptors mediate smooth
muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol
Exp Ther 1994;271:429-437.
Tan JC, Peters DM, Kaufman PL. Recent developments in understanding the pathophysiology
of elevated intraocular pressure. Curr Opin Ophthalmol 2006;17:168-174.
Tarkkanen A, Reunanen A, Kivelä T. Frequency of systemic vascular diseases in patients with
primary open-angle glaucoma and exfoliation glaucoma. Acta Ophthalmol 2008;86:598-602.
Tewksbury DA, Frome WL, Dumas ML. Characterization of human angiotensinogen. J Biol
Chem 1978;253:3817-3820.
REFERENCES
86
Tielsch JM, Katz J, Singh K, Quigley HA, Gottsch JD, Javitt J, Sommer A. A population-based
evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol. 1991;134:1102-
1110.
Tielsch JM, Katz J, Sommer A, Quiqley HA, Javitt JC. Hypertension, perfusion pressure, and
primary open angle glaucoma. A population-based assessment. Arch Ophthalmol.
1995;113:216-221.
Tigerstedt R, Bergman PG. Niere und Kreislauf. Skandinav Arch Physiol 1898;7-8:223-271.
Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, Yarski M, Smith AI,
Cooper ME. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res
2004;29:419-427.
Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR,
Saye JA, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol
Rev 1993a;45:205-251.
Timmermans PB, Wong PC, Chiu AT, Herblin WF, Smith RD. New perspectives in angiotensin
system control. J Hum Hypertens 1993b;7:19-31.
Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of
angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive
carboxypeptidase. J Biol Chem 2000; 275: 33238-33243.
Townsend DJ, Brubaker RF. Immediate effect of epinephrine on aqueous formation in the
normal human eye as measured by fluorophotometry. Invest Ophthalmol Vis Sci 1980;19:256-
266.
Triller DM, Evang SD, Tadrous M, Yoo BK. First renin inhibitor, aliskiren, for the treatment of
hypertension. Pharm World Sci 2008;30:741-749.
Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific
chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem
1990;265:22348-22357.
Vaajanen A, Luhtala S, Oksala O, Vapaatalo H. Does the renin-angiotensin system also
regulate intraocular pressure? Ann Med 2008;10:1-10.
Van den Buuse M, Malpas SC. 24-hour recordings of blood pressure, heart rate and
behavioural activity in rabbits by radio-telemetry: effects of feeding and hypertension. Physiol
Behav 1997;62:83-89.
Vapaatalo H. Pharmacology of agents for glaucoma. Vox 1995;17:19-28.
Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E,
Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human
angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002;277:14838-14843.
Vita JB, Anderson JA, Hulem CD, Irving HL. Angiotensin-converting
enzyme activity in ocular fluids. Invest Ophthalmol Vis Sci 1981;20:255-257.
Wagner J, Jan Danser AH, Derkx FH, de Jong TV, Paul M, Mullins JJ, Schalekamp MA, Ganten
D. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme
RNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J
Ophthalmol 1996:80:159-163.
REFERENCES
87
Wagner JA, Edwards A, Schuman JS. Characterization of uveoscleral outflow in enucleated
porcine eyes perfused under constant pressure. Invest Ophthalmol Vis Sci 2004;45:3203-3206.
Wang RF, Podos SM, Mittag TW, Yokoyoma T. Effect of CS-088, an angiotensin AT1 receptor
antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res 2005a;80:629-
632.
Wang WH, Millar JC, Pang IH, Wax MB, Clark AF. Noninvasive measurement of rodent
intraocular pressure with a rebound tonometer. Invest Ophthalmol Vis Sci 2005b;6:4617-4621.
Watkins RW, Baum T, Cedeno K, Smith EM, Yuen PH, Ahn HS, Barnett A. Topical ocular
hypotensive effects of the novel angiotensin converting enzyme inhibitor SCH 33861 in
conscious rabbits. J Ocul Pharmacol 1987;3:295-307.
Weinreb RN. Uveoscleral outflow: the other outflow pathway. J Glauc 2000;9:343-345.
Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;22:1711-1720.
Weinreb RN, Sandman R, Ryder MI, Friberg TR. Angiotensin-converting enzyme activity in
human aqueous humor. Arch Ophthalmol 1985;103:34-36.
Weinreb RN, Toris CB, Gabelt BAT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the
aqueous humor outflow pathways. Surv Ophthalmol 2002;47:53-64
Weitzman M, Caprioli J. Medical therapy of glaucoma. In: Duane`s Ophthalmology, Eds.
Tasman W, Jaeger EA. CD-ROM edition. Lippincot Williams et Wilkins 2006; Vol 3, Ch 56.
Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic
activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl
endopeptidase and neutral endopeptidase 24,11. Life Sci 1993;52:1461-1481.
Whitworth JA; World Health Organization, International Society of Hypertension Writing Group.
2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement
on management of hypertension.J Hypertens 2003;21:1983-1992.
Wu SY, Nemesure B, Leske MC. Observed versus indirect estimates of incidence of open-angle
glaucoma. Am J Epidemiol 2001;15:184-187.
Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. A fluorophotometric study of the effect
of topical timolol on aqueous humor dynamics. Exp Eye Res 1978;27:135-142.
Yagil Y, Yagil C. Hypothesis ACE2 modulates blood pressure in the mammalian organism.
Hypertension 2003;41:871-873.
Yamamoto Y, Komatsu T, Koura Y, Nishino K, Fukushima A, Ueno H. Intraocular pressure
elevation after intravitreal or posterior sub-Tenon triamcinolone acetonide injection. Can J
Ophthalmol 2008;43:42-47.
Yao K, Tschudi M, Flammer J, L?scher TF. Endothelium-dependent regulation of vascular tone
of the porcine ophthalmic artery. Invest Ophthalmol Vis Sci 1991;32:1791-1798.
Zhang JZ, Xi X, Gao L, Kern TS. Captopril inhibits capillary degeneration in the early stages of
diabetic retinopathy. Curr Eye Res 2007;32:883-889.
Zheng Z, Chen H, Xu X, Li C, Gu Q. Effects of angiotensin-converting enzyme inhibitors and
beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic
retinopathy. Exp Eye Res. 2007;84:745-752.
REFERENCES
88
Zhuo J, Ohishi M, Mendelsohn FA. Roles of AT1 and AT2 receptors in the hypertensive Ren-2
gene transgenic rat kidney. Hypertension 1999;33:347-353.
Zimmerman TJ, Harbin R, Pett M, Kaufman HE. Timolol and facility of outflow. Invest
Ophthalmol Vis Sci 1977;16:623-624.
89
ORIGINAL PUBLICATIONS
90
